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Abstract 
The EWS-FLI1 chimeric oncoprotein characterizing Ewing Sarcoma (ES) is a 
prototypic aberrant ETS transcription factor with activating and repressive gene 
regulatory functions. Mechanisms of transcriptional regulation, especially 
transcriptional repression by EWS-FLI1, are poorly understood. We report that EWS-
FLI1 repressed promoters are enriched in forkhead box recognition motifs, and 
identify FOXO1 as a EWS-FLI1 suppressed master regulator responsible for a 
significant subset of EWS-FLI1 repressed genes. In addition to transcriptional 
FOXO1 regulation by direct promoter binding of EWS-FLI1, its subcellular localization 
and activity is regulated by CDK2 and AKT mediated phosphorylation downstream of 
EWS-FLI1. Functional restoration of nuclear FOXO1 expression in ES cells impaired 
proliferation and significantly reduced clonogenicity. Gene-expression profiling 
revealed a significant overlap between EWS-FLI1 repressed and FOXO1-activated 
genes. Treatment of ES cell lines with Methylseleninic acid (MSA) evoked 
reactivation of endogenous FOXO1 in the presence of EWS-FLI1 in a dose- and 
time-dependent manner and induced massive cell death which was found to be 
partially FOXO1-dependent. In an orthotopic xenograft mouse model, MSA increased 
FOXO1 expression in the tumor paralleled by a significant decrease in ES tumor 
growth. Together, these data suggest that a repressive sub-signature of EWS-FLI1 
repressed genes precipitates suppression of FOXO1. FOXO1 re-activation by small 
molecules may therefore constitute a novel therapeutic strategy in the treatment of 
ES. 
 
 
 
 
This data will be published: 
 
Niedan S,  Kauer M, Aryee DNT, Meier A, Kofler R, Schwentner R, Poetschger U, 
Kontny U, Kovar H. 
Reactivation of FOXO1 expression as a novel therapeutic strategy for Ewing 
sarcoma (submitted). 
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Zusammenfassung 
Ewing Sarkome (ES), die am zweithäufigst auftretenden Tumore der Knochen und 
Weichteile bei Kindern und Jugendlichen, werden genetisch durch die Genfusion 
EWS-FLI1 als Folge einer chromosomalen Translokation charakterisiert. EWS-FLI1 
kodiert für einen äusserst potenten Transkriptionsfaktor, welcher sowohl Gen 
aktivierende als auch Gen repremierende Eigenschaften besitzt. Obwohl EWS-FLI1 
als transkriptioneller Hauptregulator in ES fungiert, ist dennoch nur sehr wenig über 
Mechanismen der Genregulation und im Speziellen, der transkriptionellen 
Repression bekannt. In dieser Arbeit konnte gezeigt werden, dass Promotoren von 
EWS-FLI1 reprimierten Genen eine Anreicherung von Motiven für Bindung von 
Forkhead Box Transkriptionsfaktoren zeigen. Des Weiteren konnte FOXO1 als ein 
EWS-FLI1 reprimierter transkriptioneller Meisterregulator identifiziert werden, welcher 
signifikant zur repressiven transkriptionellen Signatur von EWS-FLI1 beiträgt. FOXO1 
wird dabei einerseits direkt durch Bindung von EWS-FLI1 an dessen Promotor 
transkriptionell, aber auch post-transkriptionell über inhibitorische Phosphorylierung 
durch CDK2 und AKT unterdrückt, welche die sub-zelluläre Lokalisation und somit 
die transkriptionelle Aktivität von FOXO1 regulieren. Durch die funktionelle Re-
Expression von nukleärem FOXO1 konnte eine signifikant reduzierte Proliferation, als 
auch Klonogenizität in ES Zelllinien in vitro gezeigt werden. Profile von Experimenten 
zur Genexpression konnten zeigen, dass es eine signifikante Überlappung zwischen 
EWS-FLI1 reprimierten und FOXO1 aktivierten Genen gibt. Eine Reaktivierung von 
endogenen FOXO1 durch Verwendung von Methylselen Säure (MSA), im Beisein 
von EWS-FLI1, konnte eine Zeit- und Konzentrations-Abhängigkeit sowie Induktion 
von Zelltod, welcher zumindest teilweise auf die Reaktivierung von FOXO1 
zurückzuführen ist, in vitro bewirken.  Durch Verwendung eines orthotopen Maus 
Xenograft Modells konnte gezeigt werden, dass MSA behandelte Mäuse ein 
signifikant verringertes Tumor Wachstum und gleichzeitig erhöhte FOXO1 
Expression aufweisen.  
Zusammenfassend konnte gezeigt werden, dass eine EWS-FLI1 vermittelt repressive 
Sub-Signatur durch die Unterdrückung des Tumorsuppressors FOXO1 ausgelöst ist. 
Deshalb könnte die Reaktivierung von FOXO1 durch niedermolekulare Substanzen 
eine neue therapeutische Strategie zur Behandlung von ES Patienten darstellen.  
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1 Introduction 
1.1 Cancer evolution 
1.1.1 The progression model of cancer development 
The current model of cancer development is based on the central tenet that it is a 
genetic disease (Figure 1). Tumors evolve as a consequence of somatically acquired 
mutations, including base substitution, insertions and deletions of bases, 
rearrangements and changes in the copy number of DNA segments, leading to clonal 
expansion of cells in an unregulated fashion (1). However, somatic mutations are 
believed to be essentially random and accumulate throughout the lifespan of an 
individual. The effect of such mutations can be potentially accelerated by exogenous 
carcinogens or DNA repair defects (2). Functionally, somatic mutations can be 
classified into ‘passenger’ or ‘driver’ mutations based on their capability to promote 
cancer development. Whereas passenger mutations do not contribute to cancer 
development because they are neither subject to genetic selection nor they confer 
growth advantage, driver mutations are causally implicated in oncogenesis. Driver 
mutations confer growth advantage on the cancer cell, are further positively selected 
through Darwinian competition and thus enhance the cell’s evolutionary fitness to 
promote clonal out-growth and progression towards cancer (2).  
 
 
 
Figure 1: A multistep process of cancer evolution, from the fertilized egg to a single cell within 
a cancer (2). 
Passenger mutations that evolve and accumulate during an individual’s lifespan may be acquired 
while the cell lineage is phenotypically normal. This reflects both intrinsic mutations arising from 
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normal cell division and mutations caused by exogenous mutagens. Driver mutations will cause clonal 
expansion and tumor formation which may be supported by other processes such as DNA repair 
defects.   
 
Driver mutations reside, by definition, in the subset of genes known as ‘cancer genes’ 
and have thus subverted known hallmarks of cancer such as control of cell 
proliferation, differentiation, apoptosis and other homeostatic interactions with the 
tissue microenvironment (1, 3). The number of driver mutations and, hence, the 
number of cancer genes they alter varies between cancer types but probably lies 
around 5-7 as shown for breast, colorectal and prostate cancer (2) or by in vitro 
studies (4). However, genomic studies of cancer cells have shown that the number of 
drivers might be much higher than expected (5, 6). Interestingly, so far around 350 of 
the ~22.000 protein-coding genes (1.6%) have been reported to show somatic 
mutations in cancer with strong evidence to act as driver mutations (7).  
1.1.2 The ‘punctuated equilibrium’ evolutionary model 
The prevailing dogma of cancer development is characterized by the acquisition of 
driver mutations (described in section 1.1.1) in a cumulative manner over years and 
decades, resulting in a step-wise progression towards cancer development through 
increasingly malignant phenotypes (8). In contrast, there is experimental evidence 
that a more ‘punctuated equilibrium’ model may also apply to cancer development.  
For example, genome-wide telomere attrition in somatic cells that are already 
defective in DNA checkpoint response genes e.g. TP53 may lead to genomic 
instability followed by breakage of chromosomes, thus naked DNA ends serve as 
source for chromosomal rearrangements (9, 10). The resulting chromosomal end-to-
end fusions due to telomere loss can lead to cycles of dsDNA breaks followed by 
aberrant repair and further chromosomal damage in both daughter cells (11, 12). If 
these cycles of repair and breakage iterate, extensive genomic rearrangements that 
occur in only few cell cycles may arise in multiple sub-clones (13).  
In addition, it has been reported that massive chromosomal rearrangements, 
involving single or more chromosomes, can be acquired in one catastrophic event, a 
phenomenon called chromothripsis (Figure 2). This model proposes that a 
chromosome can shatter into hundreds to thousands of pieces in a single 
catastrophic event. Non-homologous end-joining stitches the pieces back together 
haphazardly, therefore generating hundreds of chromosomal rearrangements (14).  
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Figure 2: Chromosomes can break into hundreds of pieces that are stitched back together 
randomly to create highly aberrant chromosomes, a phenomenon called chromothripsis (14).  
(A) A patient with chordoma, exhibits 147 rearrangements that are inter- and intra-chromosomal. (B) 
Model of chromothripsis: a catastrophic event breaks the chromosome into many pieces that are 
randomly put together thereafter.  
 
Taken together, the progressive cancer development model may be complemented 
by a more ‘punctuated equilibrium’ model where bursts of somatic mutations accrue 
in a relatively short period of chronological time leading to massive genomic changes 
(e.g. intra- and inter-chromosomal rearrangements, deletions, formation of Double 
Minute Chromosomes) that further provoke cancer development. 
 
1.1.3 Cancer genes – the role of tumor suppressors and oncogenes 
All afore-mentioned genetic aberrations, whether they accumulate over time or they 
are generated throughout a single catastrophic event commonly can affect the 
expression and function of cancer genes, which can be divided into tumor suppressor 
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and oncogenes. Since tumor suppressor genes function in a recessive manner, 
mutation of both alleles is required to abrogate protein function thus increasing the 
probability of tumor formation. In contrast, oncogenes are dominantly acting, that is, 
mutation of just one allele can cause the development of a neoplasm (2, 15). The 
actual number of human cancer genes is still a matter of speculation but based on 
mice studies more than 2000 genes, when appropriately altered, can potentially 
contribute to cancer development (16). Approximately 90% of the known cancer 
genes are acting as oncogenes, whereas around 10% function as tumor suppressors 
(2).  
The mechanisms and patterns of mutations differ between oncogenes and tumor 
suppressors. Whereas tumor suppressors can arise from different mutations ranging 
from single base substitutions to whole deletions, which commonly result in 
abrogation of protein function, oncogenes are mainly activated by genomic 
rearrangements, missense amino acid changes, in-frame insertions, deletions or 
gene amplifications (2). Genomic rearrangements may involve two different genes 
leading to oncogenic fusion proteins or may position genes adjacent to other 
regulatory elements. Interestingly, rearranged oncogenic fusion genes were 
discovered in lung adenocarcinomas (17) and in more than half of the prostate 
cancer cases (18). 
However, cancer genes cluster on certain signaling pathways that control cell cycle, 
genome integrity, morphogenetic reactions, cell differentiation and apoptosis thus 
subverting biological pathways and processes towards cancer development (15).  
 
1.2 The forkhead box O (FOXO) family of transcription factors 
FOX transcription factors are a superfamily of proteins with a conserved 100-residue 
DNA-binding domain, the forkhead (FKH) domain. Since the original identification of 
the forkhead gene in Drosophila melanogaster more than 100 structurally related 
FOX proteins and 19 human subgroups named FOXA to FOXS have been 
discovered (19, 20). The O class includes FOXO1, FOXO3, FOXO4 and FOXO6 
(21). FOXO transcription factors have been shown to be involved in many cellular 
processes. They can induce cell cycle arrest (22-24), apoptosis and DNA repair (25-
27) or can modulate expression of genes involved in oxidative stress and cell 
differentiation (27) (see Figure 4). 
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1.2.1 Structure of FOXO proteins 
FOXO proteins function primarily in the nucleus where they either activate or repress 
target gene transcription (21).  
 
 
Figure 3: Structure of the FoxO family of transcription factors (28). 
FOXO proteins share common structural features:  transactivation domain, nuclear export and nuclear 
import signals (NLS, NES), a forkhead domain which enables DNA binding as well as conserved AKT 
phosphorylation sites.  
 
FOXO proteins bind their cognate DNA targeting sequences as monomers through 
their conserved forkhead domain that relies on fourteen protein-DNA contacts (29). 
The forkhead domain consists of three major α-helices, three β-sheets and two large 
loops resulting in a butterfly-like appearance that is described as ‘winged helix’ 
structure (29, 30). However, even though both winged loops make important 
interactions with DNA, it is the second loop that can influence the stability of DNA 
binding. Furthermore, it has been shown that the α-helix H3 serves as the primary 
DNA recognition site. Notably, most post-translational modifications, such as 
phosphorylation or acetylation that block FOXO activity, occur in these C-terminal 
basic regions of the forkhead domain to prevent transcriptional activity (Figure 3) (29, 
31). High affinity DNA binding studies have revealed that FOXO transcription factors 
specifically bind at a consensus FOXO-recognized element (FRE) with the core 
sequence motif (G/C)(T/A)AA(C/T)AA (32-34). FRE sites have been identified in 
promoters of canonical FOXO targets such as Fas ligand (FasL), insulin-like growth 
factor binding protein 1 (IGFBP1) or the apoptotic regulator BIM (25, 35). 
Furthermore, putative FOXO-target genes and their potential binding sites that have 
been identified by systematic bioinformatic approaches (36) suggest that FOXO 
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transcription factors are involved in various signaling pathways and thus, control a 
wide range of biochemical processes.  
1.2.2 Regulation of FOXO activity by post-translational modifications 
The FOXO transcriptional activity is tightly regulated on a post-translational level via 
phosphorylation, acetylation or ubiquitylation (summarized in Figure 4). 
1.2.2.1 Phosphorylation 
Insulin signaling regulates FOXO activity via Ras- and phosphatidylinositol-3-kinase 
(PI3K)-dependent pathways which activate protein kinase B (AKT). AKT 
subsequently translocates into the nucleus where it phosphorylates FOXO on three 
conserved serine/threonine (Figure 4) residues.  
 
 
Figure 4: Regulation of FOXO proteins by post-translational modifications (27).  
Growth factors induce Ras or PI3K signaling leading to AKT- or CDK2- mediated phosphorylation 
resulting in transcriptional inactivation of FOXO proteins by nuclear exclusion or Skp2 mediated 
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ubiquitylation and proteasomal degradation (A-C). CDK2-dependent phosphorylation is negatively 
regulated by DNA damage induced checkpoint kinases Chk1/Chk2 (D). On the other hand, oxidative 
stress has been shown to promote nuclear FOXO due to phosphorylation by JNK (E), JNK-dependent 
phosphorylation of 14-3-3 protein (F) or direct phosphorylation of FOXO protein by MST1 (G).  
Oxidative stress also favours the interaction of FOXO proteins with β-catenin (H). Histone acetyl-
transferases CBP and p300 inhibit the transcriptional activity of FOXO proteins but activation of SIRT1 
deacetylase can overcome this effect under oxidative stress (I).  
 
These posttranslational modifications allow FOXO proteins to bind the chaperone 
protein 14-3-3, resulting in the FOXO release from DNA and nuclear export in a 
CRM-1 dependent manner. The association between FOXO and the exportin CRM-1 
is regulated by the small GTPase Ran. Bound 14-3-3 protein prevents re-entry of 
cytosolic FOXO by masking the nuclear localization signal (NLS) and inhibits importin 
binding (37). 
In addition, CDK2 has been shown to phosphorylate FOXO1 at specific serine 
residues (S249/S298). This phosphorylation seems to be independent from AKT-
mediated phosphorylation events and also leads to FOXO1 nuclear exclusion 
through a mechanism that appears not to be affected by 14-3-3 binding (38).  
This CDK2 phosphorylation site lies in a CDK2 consensus phosphorylation sequence 
(K/R)(S/T)PX(K/R) which has been also found in human and mouse FOXO1 and 
FOXO6 but not in other FOXO family members (38). 
Besides AKT and CDK2, FOXO proteins are also phosphorylated by serum- and 
glucocorticoid-inducible kinases (SGKs) which act similar to AKT. SGKs are also 
activated by the PI3K pathway and translocate to the nucleus where they 
phosphorylate FOXO3 at the same residues that are recognized by AKT. However, 
SGKs preferentially phosphorylate serine 319 whereas AKT mainly phosphorylates 
serine 256 (39).  
In addition, FOXO1 can be phosphorylated by a dual-specificity tyrosine-
phosphorylated and regulated kinase (DYRK) at a novel phosphorylation site, serine 
329. When this site is mutated to alanine, the resulting mutant FOXO1 becomes 
predominantly nuclear in 90% of the cells whereas wild-type protein is only found 
nuclear in 75% of cells (40).  
In contrast to signaling pathways which drive FOXO proteins out of the nucleus, 
stress conditions such as oxidative stress or genotoxic stress consistently 
reconstitute nuclear FOXO proteins, even in the presence of growth factors. For 
example, CDK2-mediated phosphorylation of FOXO1 is abolished by activation of 
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checkpoint kinases Chk1 and Chk2 (38) (Figure 4). On the other hand, oxidative 
stress activates c-Jun N-terminal kinase (JNK) which in turn phosphorylates and 
activates FOXO4 at threonine 447 and threonine 451 (41). The JNK mediated 
nuclear FOXO activation seems to be evolutionary conserved since JNK antagonizes 
insulin/IGF-1 signaling in Drosophila and promotes nuclear localization of FOXO 
proteins (42). However, it seems that the JNK phosphorylation sites in FOXO4 are 
not very conserved throughout the FOXO family (43), thus, additional mechanisms 
might mediate the JNK dependent nuclear localization of FOXO proteins. One 
possibility for JNK directed nuclear FOXO regulation might be the observation that 
JNK can phosphorylate 14-3-3ξ at serine 184, causing dissociation of 14-3-3 from 
FOXO3 in the cytoplasm and finally triggers nuclear localization of FOXO3 (44) 
(Figure 4). Another JNK-related mechanism for the nuclear localization of FOXO3 
has been suggested, involving the mammalian Ste20 (yeast protein kinase Sterile 
20)-like kinase-1 (MST1) that phosphorylates FOXO3 at serine 207 (45). This 
phosphorylation blocks the interaction of FOXO3 with 14-3-3β and induces nuclear 
localization (Figure 4). However, the serine 207 site within the forkhead domain is 
conserved throughout the FOXO family and MST-FOXO interactions are also 
observed in C. elegans (45). In addition, MST1 might regulate FOXO activity through 
JNK-dependent pathways since it has been shown that MST1 can activate the JNK 
pathway in mammalian cells (46).  
1.2.2.2 Ubiquitylation 
As shown in Figure 4, FOXO proteins can be degraded by the ubiquitin proteasome 
system. FOXO1, for example, has been shown to be degraded via proteosomal 
degradation in response to AKT mediated phosphorylation. This process requires the 
interaction of FOXO1 with the F-box protein Skp2, the substrate-binding component 
of the Skp1/culin 1/F-box protein (SCFSkp2) E3 ligase complex. Interestingly, Skp2 
dependent polyubiquitylation requires preceding phosphorylation at serine 256 by 
AKT (47). Since Skp2 is a nuclear protein (48) and FOXO1 is phosphorylated by AKT 
in the nucleus as well (49), Skp2-dependent polyubiquitylation probably occurs in the 
nucleus. In contrast, FOXO4 can be monoubiquitylated in response to oxidative 
stress, leading to nuclear localization of FOXO4 and thus, increased transcriptional 
activity (50). The conserved lysine residues K199 and K211 within the C-terminus of 
the FKH domain of FOXO4 are targeted by monoubiquitylation and can be 
deubiquitylated by the herpesvirus associated ubiquitin-specific protease 
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(HAUSP/USP7) (50). Deubiquitylation of FOXO4 results in cytoplasmic localization 
and abolished transcriptional activity. Therefore, monoubiquitylation, at least for 
FOXO4, represents another important post-translational modification in cells that 
regulates the transcriptional activity of FOXO proteins. 
1.2.2.3 Acetylation 
The nuclear proteins CBP and p300 posess intrinsic histone acetyl-transferase (HAT) 
activity and, thus, have been implicated to play essential roles in promoting 
transcription. They acetylate histones and/or integrate signals from enhancer to 
promoter regions. Furthermore, it has been shown that they can directly acetylate 
transcription factors through a transcription factor acetyl-transferase (FAT) activity 
(51).  CBP, on the one hand, can acetylate chromosomal histones and therefore 
facilitates FOXO-mediated gene transcription, but on the other hand promotes 
acetylation and regulation of FOXO proteins themselves.  
In response to oxidative stress, acetylation of FOXO proteins within the nucleus 
increases (52, 53), leading to accumulation and association with Pml bodies, which 
hinders FOXO activity (54). This acetylation and nuclear accumulation can be 
abrogated by a nicotinamide adenine dinucleotide (NAD)-dependent histone 
deacetylase, SIRT1. Upon stress stimuli, nuclear SIRT1 forms a complex with FOXO 
proteins followed by FOXO-deacetylation and transcriptional reactivation (52). 
Interestingly, expression of SIRT1 increases FOXO3 induced cell cycle arrest via 
induction of p27KIP1 (52), which is consistent with the negative regulatory role of CPB 
on the FOXO transcriptional activity (55). In addition, by blocking SIRT1 activity using 
class I/II and III histone deacetylase (HDAC) inhibitors, FOXO3 induced expression 
of the apoptotic gene BIM is further enhanced (52). Thus, SIRT1 appears to function 
as fine-tuner, shifting FOXO function from cell death to survival.  
1.2.3 FOXO transcription factors function as tumor suppressors 
The ability of FOXO transcription factors to regulate the cell cycle, stress repair, 
oxidative detoxification and cell death has long suggested that they function as tumor 
suppressors (Figure 4). In line with this assumption, in most human cancers that 
have very high levels of AKT due to mutations in RAS, PTEN or PI3K, FOXO function 
is inhibited (56). As explained in the following section, recent in vivo approaches have 
shown that FOXO proteins are bona fide tumor suppressors.  
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Initially the FOXO transcription factors were discovered in some forms of leukemia 
and alveolar rhabdomyosarcoma where they evolve as fusion proteins, resulting from 
chromosomal translocations (myeloid/lymphoid or mixed lineage leukemia (MLL)-
FOXO4 and MLL-FOXO3; PAX3-FOXO1, PAX7-FOXO1) (57). In these cases, the 
FOXO transactivation domain (see Figure 3) is fused to PAX3/7 or MLL, resulting in 
maintainance of the transcriptional program of these genes, thus, leading to 
permanently active transcription factors that drive proliferation even at times when 
they should be inactive (58). Since FOXO proteins can induce cell cycle arrest and 
apoptosis, it was suggested that the fusion proteins function, to some extent, 
dependent on (partial) FOXO loss-of-function as shown for the MLL-FOXO4 fusion 
(58). Thus, the function of the afore-mentioned fusion proteins could be delineated to 
uncontrolled proliferation mediated through PAX3, PAX7 or MLL function and loss of 
the tumor suppressor function of the remaining intact FOXO allele (56).  
In vitro assays have demonstrated that mutations of specific FOXO residues that are 
required for inactivation by AKT-mediated phosphorylation can block colony 
formation in RAS-transformed cells or cells deficient for the phosphatase and tensin 
homolog (PTEN) (59).  
Furthermore, a dominant negative form of FOXO (dnFOXO) which comprises the 
DNA-binding domain, but lacks the transactivation domain, has been shown to 
substitute RAS expression in classical combinatorial RAS and MYC transformation 
studies (60). Forced expression of FOXO transcription factors can also reduce tumor 
growth in vivo using a xenograft model in nude mice (61, 62). Taken together, in vitro 
and in vivo studies indicate that FOXO proteins could function as tumor suppressors. 
The first orthotopic in vivo evidence that FOXO proteins can function as negative 
regulators of uncontrolled cell-growth came from studies performed in C. elegans. 
Since the activity of the abnormal dauer formation protein 16 (DAF-16), the 
C.elegans ortholog of FOXO, is also negatively regulated by PI3K/AKT signaling, it 
seems that the molecular mechanisms that control FOXO expression and activity 
have been conserved during evolution. Consistent with activation of mammalian 
FOXO proteins during stress by JNK-mediated phosphorylation, DAF-16 is also 
positively regulated by JNK in C. elegans. In addition, DAF-16 or FOXO (D. 
melanogaster) have been shown to extend life span (63, 64). It is likely that FOXO 
also possibly affects the life span in mammals since the mechanism of DAF-16 and 
FOXO activity seems to be evolutionary conserved. In this respect, a tumor 
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suppressor role of FOXO proteins seems plausible because escape from cancer (an 
age-related disease) is likely to prolong at least median life span (56). Further 
experimental evidence that FOXO transcription factors function as genuine tumor 
suppressors came from studies where three FOXO genes (FOXO1, FOXO3 and 
FOXO4) were simultaneously conditionally deleted (triple FOXO-knockout).  This 
caused spontaneous tumor formation in mice (65). Using dominant negative FOXO 
(dnFOXO), which, in principle, should inhibit all FOXO isoforms, enhanced 
lymphomagenesis in the E-µ-MYC mouse model (66). It is believed that FOXO can 
counterbalance MYC-induced proliferation by induction of p27KIP1 and lead to a 
lowered apoptotic threshold in MYC-transformed cells via upregulation of BIM and 
FasL (56). FOXO can also directly affect MYC-induced protein translation in 
Drosophila as a consequence of ribosome biogenesis interference (67). 
Taken together, it has been shown that FOXO proteins can counteract both 
spontaneous as well as MYC-induced tumor formation and, furthermore, that FOXO 
transcription factors can interfere with the oncogenic functions of MYC (56). 
The p53 protein mediates one of its tumor-suppressive functions through induction of 
the DNA-damage-repair response. Also FOXO proteins have been implicated in DNA 
repair via regulation of GADD45 and involvement in the ATM-mediated DNA-damage 
response (68, 69).  
FOXO transcription factors also regulate the cellular antioxidant capacity through the 
induction of genes encoding enzymes such as the manganese superoxide dismutase 
(MnSOD) or catalase. These enzymes are important to scavenge respiration-derived 
reactive oxygen species (ROS). Thus, loss of FOXO function contributes to an 
increase in cellular ROS. Even though tumor cells are more sensitive to increased 
levels of ROS than untransformed cells, they have acquired means to cope with 
higher ROS levels in the absence of FOXO by switching to glycolysis rather than 
mitochondrial respiration even in the presence of sufficient oxygen supply (Warburg 
effect) (70). 
Interestingly, FOXO transcription factors have been shown to be also involved in the 
positive regulation of autophagy during nutrient starvation through transcriptional 
regulation of BNIP3 (BCL2/adenovirus E1B 19kDa-interacting protein 3), LC3 
(microtubule-associated protein 1A/B-light chain 3), ATG12 (autophagy-related 12 
homolog) and GABA(A)-receptor associated protein-like 1 (GBRL1) (71). Autophagy 
has long been regarded as a catabolic process involving the degradation of damaged 
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or surplus organelles by the lysosomal machinery or as an alternative source of 
amino acids in times of nutrient deprivation. However, it has now become clear that 
autophagy can contribute to cancer formation and moreover that, for example, by 
blocking p53-induced autophagy using chloroquine, the oncogenic potential of MYC 
is greatly limited (72). Blocking autophagy might serve as promising strategy for 
enhancing cancer therapies because cell death through inhibition of autophagy is not 
dependent on proteins such as Bax (Bcl-2 associated X), Bak (Bcl2 homologous 
antagonist/killer) or caspase activation or ATM signaling, which are often mutated in 
cancer (73).  
The loss of FOXO protein can perturb the proliferation-apoptosis balance in 
homeostasis and provides one of many explanations on how cells can become 
tumorigenic, but for cancer to become malignant, angiogenesis is required. Tumor 
vascularization under hypoxic conditions is normally provided by up-regulation of the 
hypoxia inducible factor 1 alpha transcription factor (HIF-1α) that in turn activates the 
transcription of the secreted vascular endothelial growth factor-A (VEGF-A) (74). The 
resulting expression of VEGF functions to attract endothelial cells for the formation of 
new blood vessels (75). Interestingly, a study using the triple FOXO-knockout mouse 
(previously explained) revealed that loss of FOXO function leads to aberrant vascular 
growth and widespread hemangiomas. This indicates that FOXO transcription factors 
are obviously involved in the regulation of homeostasis of the vasculature (76). 
Furthermore, FOXO1-knockout mice die at day 10.5 due to incomplete vascular 
development (77).  
The FOXO transcription factors have been shown to also regulate HIF activity. 
Initially, HIF-1α levels where shown to be down-regulated by FOXO4 in a VHL-
independent manner (78) but two more recent studies have shed light on a molecular 
mechanism of FOXO-dependent HIF-1α transcriptional inhibition. On the one hand, 
FOXO indirectly prevents the HIF-1α-induced apoptosis by up-regulation of its target 
CBP/p300-interacting transactivator 2 (CITED2) (79). On the other hand, PTEN 
mediated activation of FOXO facilitated the titration of p300 away from HIF-1α (80).  
So far, it is not clear to what extent the role of FOXO in the regulation of 
angiogenesis under hypoxic conditions contributes to its tumor-suppressive functions. 
However, re-activation of suppressed FOXO proteins in cancer might not only control 
tumor growth via anti-proliferative or pro-apoptotic functions but could possibly also 
be beneficial by abrogating tumor angiogenesis (56).  
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1.3 Ewing Sarcoma 
Ewing Sarcoma (ES) is a very aggressive primary tumor of the bone, characterized 
by its small round cell phenotype (81, 82). ES is a malignancy of children and young 
adults with a peak incidence of ~ 15 years, making it the second most common bone 
tumor following osteosarcoma (83, 84). The primary tumor location typically is in the 
bone but in a small portion (<15%) of patients the tumor arises in soft tissue (85, 86). 
ES belongs to a group referred to as Ewing sarcoma family tumors, including Askin’s 
tumors and primitive neuroectodermal tumors, which harbour the same set of 
translocations (87-90).  
 
 
 
Figure 5: Characteristics of Ewing sarcoma (91). 
(A) Magnetic resonance image of a Ewing tumor (ET) (pelvis). (B) Typical small round cell phenotype 
of ES (H&E staining, resolution 200x). 
 
Since ES are very aggressive tumors, the propensity to metastasize to the lung, bone 
or bone marrow is very high. The current standard to treat ES patients is a 
combination of systematic chemotherapy, surgery and/or radiation (86). Despite this 
multimodal aggressive treatment, the 5-years disease free survival rate of patients 
with metastasis at diagnosis (15-25%) (92) is very low (~ 10-30%) and increases up 
to 60-70% when the disease is localized (93, 94).  
The poor prognosis for patients with metastasis and the high relapse rate for patients 
with surgically-resected ES tumors in the absence of chemotherapy (~90%) (95-97) 
clearly demonstrate the need for new treatment strategies and a better 
understanding of the biology underlying the pathogenesis of ES.  
A B 
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A major question that needs to be addressed is from which cell-of-origin the disease 
arises. Currently there is no definite answer to this question. However, there are two 
main hypothesis on the precursor cell type for ES. On the one hand, there is a 
growing body of evidence that mesenchymal stem or progenitor cells represent the 
cellular origin for Ewing sarcoma (98-101), but on the other hand, neural crest cells 
have been shown to fulfil the criteria to function as a precursor cell type for ES (102-
104). Interestingly, a recent idea suggests that maybe both hypothesis are valid to 
some extent. Either ES arise from a neural crest stem cell with mesenchymal 
features or from a mesenchymal stem cell, derived from a neural progenitor cell (105, 
106).  
The problem that the cellular origin of ES is not yet clarified is further demonstrated 
by a number of attempts to generate a mouse model for Ewing sarcoma. In one 
study, the underlying strategy to express EWS-FLI1 (see section 1.3.1), which is 
embryonic lethal when constitutively expressed, was to knock-in the gene-fusion 
under the Rosa-26 locus. The EWS-FLI1 expression was then targeted to bone 
marrow progenitor cells by crossing to mice that express the cre recombinase (Mx1-
cre) (107). However, neither these mice, nor mice from other studies, e.g. lymphocyte 
specific expression of Rag-1 cre recombinase to drive EWS-ERG expression (108, 
109), or expression of EWS-FLI1 in the primitive mesenchyme of the early limb bud 
using the Prx-cre driver (110), developed spontaneously sarcomas or only when the 
Tp53 gene was simultaneously mutated. 
In addition, it has been reported that human mesenchymal stem cells that express 
EWS-FLI1 did not form tumors in immunodeficient mice, suggesting that not only the 
cellular context but also the existence of cooperating mutations enable normal cells 
to transform to cancer cells (86).  
Another highly speculative possibility, why no other organism except humans has 
ever been reported to develop ES, is the lack of EWS-FLI1 specific GGAA-
microsatellites in non-primates (e.g. the mouse). EWS-FLI1 is supposed to bind 
these GGAA arrays to activate specific target genes which are required for the 
oncogenic phenotype of ES. If these sequences are lacking, EWS-FLI1, even though 
it’s expressed, may not be able to induce target gene promoters and, thus, formation 
of Ewing sarcoma is abrogated (86).  
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1.3.1 EWS-FLI1 
ES is genetically characterized by chromosomal translocations that result in EWS-
ETS gene rearrangements. The most frequently observed gene fusion combines 
EWS with FLI1, leading to the expression of an aberrantly active ETS transcription 
factor, EWS-FLI1 (111). About 85% of ES tumors harbor this specific 
t(11;22)(q24;q12) translocation (89, 112) involving the Ewing sarcoma break point 
region 1 (EWSR1) gene on chromosome 22 and the Friend leukemia virus integration 
site 1 (FLI1) gene on chromosome 11 (Figure 6).  
 
 
 
Figure 6: The EWS-FLI1 chimeric transcription factor characteristic of Ewing sarcoma (91). 
The N-terminal transactivation domain of the EWSR1 gene fuses to the DNA-binding domain of the 
FLI1 gene leading to formation of an aberrantly active transcription factor.  
 
The EWS protein, belonging to the TET family of proteins, normally associates with 
the transcriptional machinery including RNA polymerase II, TFIID and CPB/p300, 
suggesting a role in transcriptional activation (113-116). In contrast, the FLI1 protein 
belongs to the afore-mentioned ETS family of transcription factors and normally 
functions in vascular, neural-crest and hematopoietic development (117-119). As 
shown in Figure 6, the chimeric EWS-FLI1 protein consists of the amino-terminus of 
1 
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EWS (contains the transactivation domain) and the carboxy-terminus of FLI1 
(contains the DNA binding domain) which recognizes purine-rich sequences 
containing a GGAA/T core motif (120, 121), thus representing a typical aberrant 
transcription factor that functions as an oncogene (122, 123). However, the reciprocal 
FLI/EWS fusion is not expressed in ES tumors (89).  
The EWS-FLI1 protein is constitutively expressed from the EWSR1 promoter, 
whereas the FLI1 promoter is not functional in ES cells (86). Rearrangement of EWS-
FLI1 leads to disruption of one wild-type copy of EWSR1 and one wild-type copy of 
FLI1 in Ewing tumors (ET) (89). Since the latter is not expressed in ES it might not be 
of any importance (86), but the role or function of the EWSR1 haploinsufficiency is 
yet not well understood.  
The EWS-FLI1 protein is considered an ideal tumor specific therapeutic target (124) 
due to its exclusive presence in ES and its proven rate-limiting role in the 
pathogenesis of this disease (125). For instance, interference with EWS-FLI1 
expression or function results in tumor regression in vivo and dysregulates ES tumor 
cell growth in vitro (126-128). Since EWS-FLI1 functions as a very potent 
transcription factor, RNA-interference (RNAi) based approaches in combination with 
microarray technology revealed a number of EWS-FLI1 dysregulated genes 
downstream of the fusion protein (129-131). There is a growing list of EWS-FLI1 
regulated target genes involved in cellular processes that sustain tumorigenesis 
through regulation of the cell cycle, evasion of apoptosis, cell proliferation, drug 
resistance, evasion of growth inhibition, angiogenesis, adhesion, immortalization and 
maintainance of pluripotency (e.g. CCND1, IGFBP3, GSTM4, TGFBRII, p21, hTERT, 
VEGF, CAV and EZH2) (130, 132-137). These examples demonstrate that EWS-
FLI1 obviously regulates a whole network of downstream effector genes in a direct or 
indirect manner.  
1.3.2 Mechanisms of transcriptional regulation by EWS-FLI1 
The mechanism of transcriptional regulation by EWS-FLI1 is a growing area of 
research in the field. Whereas some studies have shown that EWS-FLI1 can regulate 
gene-expression in a DNA-binding independent manner (138, 139), there is clear 
experimental evidence that the DNA-binding property of EWS-FLI1 is indispensable 
to its oncogenic potential (140). EWS-FLI1 has been shown to up-regulate 
transcription of specific target genes by binding to a high affinity ETS binding site 
(ACCGGAAGTG) or by binding to GGAA-microsatellite repeat sequences in target 
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gene promoters (86). Experimental evidence suggests that the EWS domain confers 
transcription activating properties to the chimeric transcription factor (122, 141). 
However, knockdown of EWS-FLI1 uncovers similar numbers of EWS-FLI1 
repressed and activated genes (129). 
Kinetic studies of gene expression, using an inducible EWS-FLI1 knockdown model 
in ES cell lines (our unpublished data), revealed that CGGAAT motifs are particularly 
enriched in early down-regulated genes (EWS-FLI1 activated). Interestingly, this 
presumably directly activated target genes also show enrichment for other 
transcription factor binding motifs such as E2F, NRF1 and NFY, suggesting a model 
of transcription factor cooperation to activate gene transcription. Furthermore, a 
ChIP-seq study has shown that combinations of two ETS binding sites were 
frequently found in non-microsatellite EWS-FLI1 binding regions, suggesting that, for 
at least some promoters, EWS-FLI1 homo- or hetero-dimerizes with other ETS 
transcription factors to activate target gene transcription (142).  
This model is further supported by a study showing that cooperative DNA binding of 
EWS-FLI1 with Fos-Jun (AP-1) is required to activate the expression of uridine 
phosphorylase (UPP) mRNA and to transform 3T3 fibroblasts in vitro. In contrast, a 
C-terminally truncated mutant version of EWS-FLI1 failed to activate UPP 
transcription and 3T3 fibroblast transformation as a consequence of a deficient 
cooperative DNA binding ability (143).  
Direct protein interactions represent another intriguing mode of transcriptional 
regulation by EWS-FLI1. It has been shown that EWS-FLI1 not only binds to DNA but 
also directly interacts and binds to proteins of the transcriptional apparatus such as 
the hRBP7 subunit of RNA polymerase holoenzyme II (Pol II) (114) or the Creb-
binding protein (CBP) (144). Another interesting binding partner of EWS-FLI1 is the 
RNA helicase A (RHA). RHA functions as part of the basal transcriptional apparatus 
(145) and is also involved in the posttranscriptional RNA metabolism (146). It has 
been shown that the interaction of EWS-FLI1 with RHA is required for optimal 
transformation of murine fibroblasts (147). In contrast, reduced EWS-FLI1 activity 
and tumorigenesis was observed when binding of EWS-FLI1 to RHA was blocked 
(126). 
Interestingly, it has been shown that EWS-FLI1 can form ternary complexes with 
serum response factors (SRFs) to recognize and bind serum response elements 
(SREs) within promoters of target genes such as c-fos or Erg1 (148, 149).  
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In addition, components of the splicing machinery such as U1C protein were 
identified as binding partners of EWS-FLI1, suggesting an important 
posttranscriptional regulatory role of the chimeric oncoprotein (150). Interestingly, 
EWS-FLI1 showed altered splice site selection of the E1A (151) as well as cyclin D 
transcript, the latter giving rise to a more stable cell cycle agonist (152). Other 
proteins that are associated with the EWS-FLI1 spliceosome, but not identified as 
directly binding to EWS-FLI1, are TASR proteins (153) and YB-1 (154). 
Furthermore, protein-protein interactions can be influenced by posttranslational 
modifications such as O-GlcNAcylation, a modification that has been shown to 
enhance the transcriptional activity of EWS-FLI1 and seems to be reciprocally related 
to phosphorylation (155). However, the effects of posttranslational modifications on 
protein-protein interactions and on overall ES cellular growth remain elusive. 
 
1.3.2.1 Transcriptional repression 
The mechanisms of transcriptional regulation by EWS-FLI1 are only partially 
understood. So far, very little is known about mechanisms of EWS-FLI1 mediated 
gene repression, even though there is evidence that a subset of genes is indirectly 
repressed by EWS-FLI1.  
On the one hand, EWS-FLI1 repressed genes (activated upon inducible knockdown 
of EWS-FLI1) did not show any enrichment of ETS binding motifs in our in silico 
analysis (129) or in the afore-mentioned ChIP-seq study (142). On the other hand, 
binding motifs for a large number of other transcription factors were identified in 
proximal promoter regions of EWS-FLI1 repressed genes, suggesting an indirect 
mechanism of EWS-FLI1 mediated gene repression in ES.  
Experimental evidence for such indirect repressive mechanisms evolved by a study 
showing that part of the EWS-FLI1 repressive signature can be assigned to the 
activation of transcriptional repressors such as NKX2.2 or NR0B1 (156, 157). EWS-
FLI1 directly activates NKX2.2, which encodes for a dual-function homeodomain 
transcription factor whose repressive function is mediated by recruiting Groucho-
family co-repressors. The NKX2.2 repressed gene-set highly overlapped with the 
EWS-FLI1 downregulated signature. Furthermore, NKX2.2 functionally mediated 
oncogenic transformation via transcriptional repression since structure-function 
analysis revealed that the DNA binding and repressor domains of NKX2.2 were 
required for oncogenesis in ES cells (156). Whereas NKX2.2 represents a 
26 
downstream target of EWS-FLI1, NR0B1 was found to physically interact with EWS-
FLI1 and to coordinately modulate gene-expression (157).  
Another interesting study has shown that EWS-FLI1 can mediate gene repression via 
both transcriptional and posttranscriptional mechanisms (158). Whereas one EWS-
FLI1 mediated repressive mechanism functioned via decreased levels of Pol II at 
promotors of repressed genes, EWS-FLI1 was also found to decrease the half-life of 
insulin-like growth factor binding protein 3 (IGFBP3), a down-regulated direct target 
of EWS-FLI1. These findings suggest that EWS-FLI1 can modulate both transcript 
synthesis and degradation, leading to a steady-state target gene expression.  
Another mode of EWS-FLI1 induced gene repression may involve epigenetic 
mechanisms, since several genes whose gene products function in histone-
modification are among EWS-FLI1 activated targets. For example, the histone methyl 
transferase Enhancer of Zeste homolog 2 (EZH2) gene-promoter was found to be 
bound by EWS-FLI1 in vivo and, furthermore, that down-regulation of EZH2 by RNA 
interference suppressed oncogenic transformation by inhibiting clonogenicity in vitro 
(136). EZH2 is part of the enzymatic subunit of the polycomb PRC2 complex and 
mediates gene silencing by methylation of histone H3 Lys27. Interestingly, silencing 
of EZH2 in ES cells revealed a general loss of H3 Lys27 methylation and increased 
H3 acetylation, leading to gene activation (159).  
Other mechanisms of gene repression mediated by EWS-FLI1 may evolve from the 
identification of microRNAs (miRNAs) that are regulated by the oncogenic fusion 
protein. Our group has recently identified mir-145 as a top EWS-FLI1-repressed 
miRNA, whose ectopic re-expression dramatically decreased expression of EWS-
FLI1 protein and also reduced growth of ES cell lines in vitro (160). Another study 
revealed that a group of miRNAs, strongly repressed by EWS-FLI1, can negatively 
regulate the expression of IGF-1 and IGF-1R, suggesting that EWS-FLI1 utilizes 
repression of tumor-suppressive miRNAs to de-repress IGF signaling (161).  
However, to fully appreciate the role of miRNAs in the context of ES-specific gene 
expression, large-scale proteomic studies for ES will be required, since miRNAs 
rather affect protein translation than mRNA levels (162).  
Since the mechanisms and mediators of transcriptional regulation by EWS-FLI1 are 
poorly understood, a better understanding of how the fusion protein mediates 
transcriptional activation and/or repression will help to identify novel opportunities for 
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therapeutic intervention since it has been difficult to directly target nuclear 
transcription factors.  
 
1.4 Aim of the thesis 
The mechanisms of transcriptional repression by EWS-FLI1 are poorly understood. 
Based on time-course experiments following EWS-FLI1 knockdown in combination 
with expression analysis in different ES cell lines, a subset of EWS-FLI1 activated 
and EWS-FLI1 repressed genes was identified. Interestingly, in-silico motif analysis 
revealed enrichment of recognition motifs for forkhead box (FOX) proteins within 
promoters of EWS-FLI1 repressed genes. In contrast, EWS-FLI1 activated promoters 
exhibited enrichment for ETS binding sites that were not over-represented in EWS-
FLI1 repressed promoters.  
The aim of this thesis, therefore, was to investigate whether FOX transcription factors 
are involved in the EWS-FLI1 mediated gene repression. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Media 
 
RPMI 1640 with GlutaMAXTm-I 
Invitrogen, Groningen, Netherlands 
Add 10% fetal calf serum (FCS Gold, PAA Laboratories, Linz, Austria) and 100.000 
Units/l penicillin / streptomycin (PAA Laboratories, Linz, Austria) 
 
DMEM 
Invitrogen, Groningen, Netherlands 
1000 mg/L glucose, 4mM L-glutamine and 110 mg/L sodium pyruvate 
Add 10% fetal calf serum (FCS Gold, PAA Laboratories, Linz, Austria) and 100.000 
Units/l penicillin / streptomycin (PAA Laboratories, Linz, Austria) 
 
Luria Broth (LB) 
1% Trypton,  
1% NaCl,  
0,5% Yeast-extract; LB was autoclaved  
 
Opti-MEM: Invitrogen, Groningen, Netherlands 
 
Trypsin / EDTA: PAA Laboratories, Linz, Austria 
 
FCS/Accutase: PAA Laboratories, Linz, Austria 
 
2.1.2 Buffers 
 
TBS-T: 50mM Tris, 150mM NaCl, 0,1% Tween 20; pH 7,5 
 
TBS: 50mM Tris, 150mM NaCl, pH 7,5 
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PBS: 137mM NaCl; 3mM KCl; 6,5mM Na2HPO4-2H2O; 1,5mM KH2PO4 
 
Laemmli buffer 
15,1g Tris 
72g glycine 
25ml 20% SDS 
per 1 liter 
 
4% Paraformaldehyde (PFA) (100ml) 
25ml of 16% ultra pure Formaldehyde 
+ 75ml ddH2O 
 
PBS/5%TritonX-100 & PBS/2%FCS (100ml) 
5ml Triton X100, 2ml FCS 
+ corresponding volume of PBS 
 
Transfer buffer 
14g glycine 
3g Tris 
20% methanol 
per 1 liter 
 
2x sample buffer  
20% (v/v) glycerol 
6% ß-mercaptoethanol 
3% SDS 
125mM Tris-Cl pH 6,8 
small amount of bromphenol blue crystals 
 
Ponceau S staining solution (10x stock) 
2g Ponceau S 
30g trichloroacetic acid 
30g 5-sulfosalicylic acid 
fill up to 100ml with dH20 
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Loading Dye 
4M Urea 
80mM EDTA 
10% Saccharose 
0,25% BPB 
 
TBE 
5,4g Tris Base 
2,75g Boric Acid 
2ml 0,5M EDTA/pH8 
per 1 liter 
 
Blocking solution 
10% (v/v) blocking reagent (Roche, Basel, Switzerland) in maleic acid buffer (100mM 
Maleic Acid, 150 mM NaCl, pH= 7.5, sterile).  
 
2.1.3 Chemicals 
 
Probidium Iodide (PI): (P4170) Sigma, St. Louis, USA 
 
DAPI: Sigma-Aldrich, St.Louis, MO, USA   
 
Roscovitine: Sigma-Aldrich, St.Louis, MO, USA   
 
Methylseleninic Acid (MSA): Sigma-Aldrich, St.Louis, MO, USA   
 
LY294002: Merck, Darmstadt, Germany 
 
Doxycycline: Sigma, St. Louis, USA 
 
Puromycin : Sigma, St. Louis, USA 
 
Zeocin: Cayla, Toulouse, France 
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Blasticidin: Invitrogen, Groningen, Netherlands 
 
Ampicillin: Biomol, Hamburg, Germany 
 
Trypan blue: Sigma, St. Louis, USA 
 
 
2.1.4 Ewing tumor cell lines 
 
TC252 
Established by T. Triche (Dep. of Pathology, Children’s hospital, Los Angeles, USA); 
p53 wild type, expresses the type I (Exon 7 [EWS]/ Exon 6 [FLI1]) EWS-FLI1 fusion.  
 
SK-N-MC 
Established by J. Biedler (Memorial Sloan Ketternig Cancer Center, New York, USA); 
truncated p53, expresses the type I EWS-FLI1 fusion, derived from pPNET localized 
within the rib.  
 
A673 and A673sh (ASP14) 
The A673 ES cell line (purchased at American Type Culture Collection) expressing 
type I EWS-FLI1 fusion and doxycycline-inducible short hairpin RNA against EWS-
FLI1 (A673sh) was previously described (133) and kindly provided by Javier Alonso 
(Departamento de Biología Molecular y Celular del Cáncer, Instituto de 
Investigaciones Biomédicas, Madrid, Spain). 
 
2.1.5 Antibodies 
 
 α-FOXO1 (rabbit monoclonal, Cell Signalling, C29H4) [WB,1:1000] detects 
endogenous levels of total FOXO1 protein: 78-82 kDa. The antibody does not 
detect exogenously expressed family members FOXO3 or FOXO4. 
 
 α-Phospho-FoxO1 (Ser256) (rabbit polyclonal, Cell Signaling, # 9461) 
[WB,1:1000] detects phosphorylated Serin 256 (major AKT p-site): 82kDa 
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 α-CDK2 (rabbit polyclonal, Santa Cruz, sc-163) [WB,1:500] detects human 
CDK2: 34 kDa  
 
 α-ERK2 (mouse monoclonal, Santa Cruz, sc-65981) [WB,1:200] detects ERK2 
full length: 42 kDa 
 
 α-DYKDDDDK Tag Antibody (Anti-FLAG) (rabbit polyclonal, Cell Signaling, 
#2368) [WB: 1:1000, for IF:1:800] recognizes FLAG-Tag 
 
 α-FOXO3a (FKHRL1; rabbit polyclonal, Santa Cruz, sc-11351 (H-144)) 
[WB,1:200] detects endogenous FOXO3a: 97kDa 
 
 α-Phospho-FoxO3a (Ser253) (rabbit polyclonal, Cell Signaling, #9466) 
[WB,1:1000] detects phosphorylated Serin 253 (major AKT p-site): 97kDa 
 
 α- Tubulin (mouse monoclonal (DM1A), #CP06) [WB,1:1000] detects tubulin: 
50kDa 
 
 α-LAMIN A/C (rabbit polyclonal, Cell Signaling, #2032) [WB,1:1000], Lamin 
A/C antibody detects endogenous levels of total full length lamin A (and lamin 
C) :70 kDa 
 
 α-p-AKT (rabbit monoclonal, (244F9) Cell Signaling(Ser473), #4056) 
[WB,1:1000], Phospho-Akt (Thr308) (244F9) Rabbit mAb detects endogenous 
levels of Akt only when phosphorylated at threonine 308: 60kDa 
 
 α-AKT (rabbit polyclonal, Cell Signaling, (#9272) [WB, 1:1000] detects 
endogenous levels of total Akt1, Akt2 and Akt3 proteins. 
 
 α-β-actin to beta Actin, (mouse monoclonal, Abcam, Cambridge Science 
Park, Cambridge, UK, ab8226) [WB,1:10000] 
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 α-POD-mouse (product no. 31430, Pierce, Rockford Illinois, USA) Anti-Mouse 
IgG, (H+L), Peroxidase conjugated secondary antibody using 
chemiluminescence. [WB,1:10000] 
 
 α-POD-rabbit (product no. 31460, Pierce, Rockford Illinois, USA) Anti-Rabbit 
IgG, (H+L), Peroxidase conjugated secondary antibody using 
chemiluminescence [WB,1:10000] 
 
 goat α-rabbit IgG secondary Ab (red fluorescent Alexa 594, Molecular 
Probes, Eugene, OR) [IF,1:1000] 
 
 goat α-mouse IgG, DyLightTM 800 (green fluorescent Ab) [WB, 1:10000] 
 
2.1.6 Plasmids 
 
 pSuper∆RV: pSUPER-based retroviral mammalian expression vector. (Gift 
from Reuven Agami, Division of Tumor Biology, Netherlands Cancer Institute, 
Amsterdam, Netherlands) 
 
 pCDNA3-FLAG-FOXO1wt: was a gift from Dr. Guan (Department of 
Pharmacology, University of California, San Diego, CA).  
 
 pECE-FLAG-FOXO3a wt: were purchased from Addgene (Cambridge, MA) 
 
 pBS/U6shCDK2 and pBS/U6 empty were kindly provided by Dr. Shi (Harvard 
Medical School, Boston, MA) 
 
 pCDNA3-FLAG-FOXO1-AAA(T24A/S256A/S319A) were purchased from 
Addgene (Cambridge, MA) 
 
 pCDNA3.1-FLAG-FOXO1-S249A and pCDNA3.1-FLAG-FOXO1-
S249A/S298A was a gift from H.Huang & D.J.Tindall (Department of 
Biochemistry and Molecular Biology, Rochester, MI) 
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 pRS-shFOXO1#1(TGACTTGGATGGCATGTTCATTGAGCGCT) 
pRS-shFOXO1#2 (AATTCGGTCATGTCAACCTATGGCAGCCA) 
pRS-shFOXO1#3 (GAAGAGCTGCATCCATGGACAACAACAGT)  
pRS-shFOXO1#4 (CATCATTCGGAATGACCTCATGGATGGAG) and  pRS-
sh-scrambled were purchased from Origene (Rockville, MD) 
 
 MSCV-MIGR1: MSCV-based retroviral construct expressing low levels of 
eGFP (described in (163)) was kindly provided by M. Busslinger (Institute of 
Molecular Pathology, Vienna, Austria). 
 
 
2.1.7 Oligonucleotides 
2.1.7.1 RT-PCR 
 
BTG1:   
forward primer CCGTGTCCTTCATCTCCAAG 
reverse primer: TCGTTCTGCCCAAGAGAAGT 
product size: 423 bp 
 
GADD45a:  
forward primer CAGAAGACCGAAAGGATGGA 
reverse primer: TCCCGGCAAAAACAAATAAG 
product size: 416 bp 
 
CDKN1A:  
forward primer: GAGGCCGGGATGAGTTGGGAGGAG  
reverse primer: CAGCCGGCGTTTGGAGTGGTAGAA 
product size: 197 bp 
 
EWS-FLI1:   
forward primer: TCCTACAGCCAAGCTCCAAGTC 
reverse primer: ACTCCCCGTTGGTCCCCTCC 
product size: 328 bp 
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FOXO1:  
forward primer: AAGAGCGTGCCCTACTTCAA 
reverse primer: CATCCCCTTCTCCAAGATCA 
product size: 454 bp 
 
FOXO3:  
forward primer: TTCAAGGATAAGGGCGACAG 
reverse primer: CAGGTCGTCCATGAGGTTTT 
product size: 591 bp 
 
LOX:  
forward primer: CAGAGGAGAGTGGCTGAAGG 
reverse primer: GTGAAATTGTGCAGCCTGAG 
product size: 363 bp 
 
DDIT4:  
forward primer: AGACACGGCTTACCTGGATG 
reverse primer: AGAGTTGGCGGAGCTAAACA 
product size: 391 bp 
 
PLAT: 
forward primer: GCTACTTTGGGAATGGGTCA 
reverse primer: ATGTTCTGCCCAAGATCACC 
product size: 483 bp 
 
HEY1: 
forward primer: CGAGGTGGAGAAGGAGAGTG 
reverse primer: CGAAATCCCAAACTCCGATA 
product size: 339 bp 
 
β-ACTIN:  
forward primer: GCCGGGAAATCGTGCGTG 
reverse primer: GGGTACATGGTGGTGCCG 
product size: 305 bp 
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EPAS1: 
forward primer: CGCCATCATCTCTCTGGATT 
reverse primer: CTGGGTACTGCATTGGTCCT 
product size: 328 bp 
 
 
2.1.7.2 RT-qPCR 
 
EPAS1: 
forward primer: AAGCCTTGGAGGGTTTCATT 
reverse primer: TCATGAAGAAGTCCCGCTCT 
Probe: TGACCCAAGATGGCGACATG 
Product size: 234 bp 
 
MME: 
forward primer: CCTTCTTTAGTGCCCAGCAG 
reverse primer: CCAGTCAACGAGGTCTCCAT 
Probe: CGGCATGGTCATAGGACACG 
Product size: 131 bp 
 
OSMR: 
forward primer: GTCATCTGGGTGGGGAATTA 
reverse primer: CAAAGTGTGTGGCACATTCC 
Probe: TTCTGCATTGGAGCTGGGAA 
Product size: 100 bp 
 
B2M: 
forward primer: TGAGTATGCCTGCCGTGTGA 
reverse primer: TGATGCTGCTTACATGTCTCGAT 
Probe: CCATGTGACTTTGTCACAGCCCAAGATAGTT 
Product size: 82 bp 
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EWS-FLI1(typeI): 
forward primer: CAGCCAAGCTCCAAGTCAATATAG 
reverse primer: GCTCCTCTTCTGACTGAGTCATAAGA 
Probe: CTGCCCGTAGCTGCTGCTCTGTTG 
Product size: 84 bp 
 
FOXO1: 
forward primer: AAGAGCGTGCCCTACTTCAA 
reverse primer: GTTGTTGTCCATGGATGCAG 
Probe: CGGCGGGCTGGAAGAATTCA 
Product size: 207 bp 
 
 
2.1.7.3 ChIP-PCR 
 
FOXO1 promoter (Chr.13): covering ChIP seq. hit  
forward primer: GCCCGACTTACGGGATCT 
reverse Primer: GAGAAAAACACCCCACTACCC 
Product size: 197 bp at position -609/-412 
 
FOXO1 promoter (Chr.13): upstream of ChIP seq hit but probably also covered due 
to fragment size (shearing) 
forward primer: CCGGCGACACTTTGTTTACT 
reverse Primer: CGTTCAGCAAAGACATCGTG 
Product size: 225 bp at position -961/-736 
 
FOXO1 control (Chr. 13): ~ 9kb upstream of TSS, predicted to contain no ETS sites 
(Consite) 
forward primer: CAGAGTCCCTCGGTCATCTC 
reverse Primer: TGCGTTGTTGATTTTCTGCT 
Product size: 183 bp at position -9071/-8888 
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2.1.8 Kits 
 
MAGnifyTM Chromatin Immunoprecipitation System Kit: 
MAGnifyTM Chromatin Immunoprecipitation System Kit (Invitrogen, Groningen, 
Netherlands) was used to perform ChIP experiments following the manufacturer’s 
instructions. (see also, section 1.3 Methods, Chromatin immunoprecipitation assay) 
  
SuperSignal® West Femto Maximum Sensitivity Substrate Kit: 
SuperSignal® West Femto Maximum Sensitivity Substrate Kit is an extremely 
sensitive enhanced chemiluminescent substrate for detecting horseradish peroxidase 
(HRP) on western blots. (34096, Thermo Fisher Scientific, USA) 
 
Nuclei EZ prep nuclei isolation Kit: 
Nuclei EZ prep nuclei isolation Kit (NUC-101, Sigma, Saint Louis, MO) was used to 
prepare cytoplasmic/nuclear cell fractions according to the manufacturer’s 
instructions.  
 
Bright-GloTM Luciferase assay Kit: 
Bright-GloTM Luciferase assay Kit (Promega, Madison, WI) was used for reporter 
gene assays according to the manufacturer’s recommendations.  
 
NE-PER Nuclear and Cytoplasmic Extraction Reagents: 
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, 
Rockford, USA; distributor Thermo Scientific, product no.78833) was used to 
separate nuclear and cytoplasmic protein fractions from fresh tumor tissues 
according to the manufacturer’s recommendations.  
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2.2 Methods 
 
2.2.1 DNA/RNA methods 
 
2.2.1.1 RNA extraction 
RNA extraction was performed using the RNAeasy Mini Kit (Qiagen, Austin, USA) 
according to the manufacturer’s instructions. 
 
2.2.1.2 cDNA synthesis 
5µg of total RNA was denatured at 70°C for 10 minutes. After 2 min on ice, master 
mix, containing MMLV reverse transcriptase (Promega, Madison, USA), random 
hexamer primers and dNTP’s were incubated for 90 min at 37°C. Subsequent 
addition of RNase free water was followed by incubation for 5 min at 70°C; cDNA 
was stored at -20°C. 
 
2.2.1.3 RT-PCR 
Standard RT-PCR was performed on 20-50ng cDNA template, mixed with a 
nucleotide mix, containing 2,5mM of dCTP, dATP, dTTP and dGTP (Promega, 
Madison, USA), 511 Reaction Buffer, (Finnzymes, Espoo, Finnland) containing 
15mM MgCl2, 0,4µM of each primer, and 0,5µl DyNAzyme DNA Polymerase (2U/µl, 
Finnzymes, Espoo, Finnland). The mix was filled up with ddH2O to a total volume of 
50µl per PCR reaction.  
The polymerase chain reaction was performed by using the Dyad-Disciple thermal 
cycler (Biorad, California, USA) under following conditions: 
Denaturation at 95°C for 2 min,  95°C for 1 min, specific annealing temperature, 
between 50-70°C, for 30 sec, elongation at 72°C for 1 min, all for the first 10 x cycles. 
This programme was slightly modified for the next 25 x cycles: 95°C for 30 sec, 
annealing temperature for 15 sec, elongation at 72°C for 1 min 30 sec, 72°C for 10 
min and 15°C forever.  
Following optimized PCR conditions could be obtained: 
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EPAS1  
[20ng] cDNA; 10pmol/µl primer; annealing: 61.8°C; 1.5mM MgCl2; x35cycles, 
elongation 1’-1’30’’ 
 
HEY1 
[20ng] cDNA; 10pmol/µl primer; annealing: 61.8°C; 3.0mM MgCl2; 4% DMSO; 
x35cycles; elongation 1’-1’30’’ 
 
PLAT 
[20ng] cDNA; 10pmol/µl primer; annealing: 58.4°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
 
DDIT4 
[20ng] cDNA; 10pmol/µl primer; annealing: 61.8°C; 1.5mM MgCl2; x35cycles; 
elongation  
1’-1’30’’ 
 
FOXO1 
[20ng] cDNA; 20pmol/µl primer; annealing: 64.6°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
 
EWS-FLI1 
[20ng] cDNA; 20pmol/µl primer; annealing: 64.6°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
  
β-actin 
elong. 1'-1'30''; annealing: 58.4°C x 22cycles; 20pmol/µl; 1.5mM MgCl2;  
 
FOXO3 
[20-50ng] cDNA; 20pmol/µl primer; annealing: 61.8°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
 
GADD45a 
[20-50ng]cDNA; 20pmol/µl primer; annealing: 61.8°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
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CDKN1A 
[20-50ng]cDNA; 20pmol/µl primer; annealing: 61.8°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
 
BTG1 
[20-50ng]cDNA; 20pmol/µl primer; annealing: 61.8°C; 1.5mM MgCl2; x35cycles; 
elongation 1’-1’30’’ 
LOX 
[20-50ng]cDNA; 20pmol/µl primer; annealing: 64.6°C; 1.5mM MgCl2; x28cycles; 
elongation 1’-1’30’’ 
 
2.2.1.4 RT-quantitative PCR (RT-qPCR) 
5µg of total RNA was denatured at 70°C for 10 minutes. After 2 min on ice, master 
mix, containing MMLV reverse transcriptase (Promega, Madison, USA), random 
hexamer primers and dNTP’s were incubated for 60 min at 37°C. Subsequent 
incubation for 30 min on 42°C and addition of RNase free water was followed by 
incubation for 5 min at 70°C; cDNA was stored at -20°C. 
Reactions were set up in a total volume of 25µl containing 12,5µl 2x Universal PCR 
Master Mix (Applied Biosystems, Vienna, Austria) and 900nM (EWS-FLI1, β2M, 
EPAS1, OSMR, MME, FOXO1) of each primer and 250nM (EWS-FLI1, β2M, EPAS1, 
OSMR, MME, FOXO1) TaqMan probe (5’-FAM, 3’-TAMRA), and 2µl of cDNA 
template (5-10ng/reaction). The mixtures were prepared in 96-well optical microtiter 
plates and amplified on the ABI Prism 7900 Sequence Detection System (Applied 
Biosystems, Foster City, CA) using the following cycling parameters: 2 min at 50°C, 
10 min a 95°C, and 40 cycles of 15s at 95°C and 60s at 60°C. The beta-2-
microglobulin values were used for normalization.   
2.2.1.5 Chromatin immunoprecipitation assay 
ChIP experiments were carried out according to the manufacturer’s instructions 
(MAGnifyTM Chromatin Immunoprecipitation System Kit, Invitrogen, Groningen, 
Netherlands). To cross-link DNA and protein, A673sh cells were treated with 1% 
formaldehyde for 10 min at room temperature. Cells were kept on ice and washed 
twice with ice-cold PBS. After centrifugation, 50µl of lysis buffer per million cells 
including protease inhibitors were applied. After sonication, using the Bioruptor UCD-
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200 TM power up sonication system (Diagenode, Liège, Belgium), the lysates were 
cleared by centrifugation. For immunoprecipitation, 15µl of FLI1 Ab (MyBioSource, 
San Diego, CA) were used. PCR was performed using Phusion Hotstart II 
polymerase (Finnzymes, Espoo, Finland). Primers were used in 40 cycles of 
amplification. 
2.2.1.6 Maxi Prep 
The day prior to preparation, 250ml of LB (containing 10mg/ml ampicillin) were 
inoculated with a pre-culture of the corresponding plasmid and incubated at 37°C 
overnight. Qiagen Endotoxin free MaxiPrep kit (Qiagen, Austin, USA) was used for 
preparation according to the manufacturer’s instructions.  
2.2.1.7 Reporter gene assays 
For firefly luciferase reporter assays, a CDK2 (-122/+458 from the TSS) promoter 
fragment was cloned into the pGL4.10 vector (Promega, Madison, WI). A673sh cells 
were co-transfected with the pGL4.10-based reporter constructs and pmaxEGFP 
(Amaxa GmbH, Cologne, Germany) using Lipofectamine Plus reagent (Invitrogen, 
Groningen, Netherlands) at 20% density. The cells were treated with doxycycline 48h 
after transfection, and gene reporter assays were carried out using Bright Glo 
Luciferase assay kit (Promega, Madison, WI) 96h after transfection (48h after 
doxycycline induction). To correct reporter activity for transfection efficiency, the 
number of EGFP positive cells was monitored by standard flow cytometry. 
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2.2.2 Protein methods 
 
2.2.2.1 SDS- Polyacrylamide Gel Electrophoresis (PAGE) 
 
The SDS- polyacrylamide gel consists of a stacking and a separating gel: 
Seperating gel: 
 6% 8,5% 12,5% 
30%Acrylamid / 0,8% Bis 1,05ml 1,4ml 2,1ml 
H2O 2,625ml 2,275ml 1,575ml 
1,5M Tris pH8,8 1,25ml 1,25ml 1,25ml 
20% SDS 25µl 25µl 25µl 
10% APS 50µl 50µl 50µl 
TEMED 6µl 6µl 6µl 
 
 
Stacking gel: 
30%Acrylamid / 0,8% Bis 415µl 
H2O 1,7ml 
1M Tris pH6,8 315µl 
20% SDS 12,5µl 
10% APS 25µl 
TEMED 2,5µl 
 
 
Cells were counted and adjusted to a concentration of 30.000 cells/ µl with PBS and 
the same volume of 2x sample buffer. Samples were boiled for 10 min at 96°C, 
followed by centrifugation at top speed, and finally loaded on the SDS-gel. The gel 
was run at 40mA for ~ 60 min, till the bromhenol blue front began to phase out.  
 
2.2.2.2 Western Blot 
 
The transfer was started by assembling the transfer unit, consisting of the typical 
sandwich conformation (sponge, 3x Whatman paper, gel, nitrocellulose membrane, 
3x Whatman paper, sponge), which was put in the blotting tank. The transfer effected 
for 90 min at 400mA with blotting tank cooled on ice.  
44 
The nitrocellulose membrane was stained with 1x PonceauS solution for several 
minutes and scanned afterwards. To avoid unspecific binding of the primary antibody, 
the membrane was incubated in 1% blocking solution for 60 minutes at room 
temperature. The primary antibody was diluted in 0.5% blocking solution, added to 
the membrane and incubated overnight at 4°C. On the next day, the membrane was 
washed three times with TBST and once with 0.5x blocking solution for 10 minutes at 
room temperature. Again, the secondary antibody was diluted in 0.5% blocking 
solution and incubated with the membrane for 1h at room temperature, followed by 
three times washing with TBST. The membrane was then carefully rinsed once with 
deionized water and incubated, with appropriate dilution of SuperSignal® West 
Femto Maximum Sensitivity Substrate Kit (Thermo Fisher Scientific, USA), for 3- 5 
minutes in the dark. Films were developed using a standard radiograph processor 
(AGFA, CP-1000). 
For detection by LICOR, Odyssey® Infrared Imaging System, a green fluorescent 
labelled secondary antibody (goat α-mouse IgG, DyLightTM 800) was diluted in 
Blocking Buffer (Odyssey infrared Imaging System, Part No.: 927-40000) and 
incubated for 1h at room temperature in the dark. The membrane was washed thrice 
with TBST and finally kept in PBS. 
 
2.2.3 Cell culture techniques 
 
ES cell lines SK-N-MC and TC252 used in this study have been previously described 
(164, 165). The A673 ES cell line expressing type I EWS-FLI1 fusion and 
doxycycline-inducible short hairpin RNA against EWS-FLI1 (A673sh) was previously 
described (133) and kindly provided by Javier Alonso (Departamento de Biología 
Molecular y Celular del Cáncer, Instituto de Investigaciones Biomédicas, Madrid, 
Spain). A673 (American Type Culture Collection), TC252 and SK-N-MC cells were 
maintained in RPMI 1640 (Invitrogen, Groningen, Netherlands) and supplemented 
with 10% FCS (PAA Laboratories, Linz, Austria). A673sh cells were maintained in 
DMEM (Invitrogen) supplemented with 10% FCS (PAA), 2µg/ml Blasticidine 
(Invitrogen) and 50µg/ml Zeocin (Cayla, France). EWS-FLI1 knockdown was induced 
by addition of 1µg/ml doxycycline (Sigma-Aldrich, St. Louis, MO). The CDK2 inhibitor 
roscovitine as well as methylseleninic acid (MSA) (Sigma-Aldrich) and the PI3K/AKT 
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inhibitor LY294002 (Merck, Darmstadt, Germany) were added to ES cells at 
concentrations and for time periods indicated in the figures. 
2.2.3.1 Transfection 
 
For plasmid transfections, A673sh, A673, SK-N-MC and TC252 ES cells were plated 
in 75-mm2 culture flasks, or directly cultured on glass slides and grown to about 70% 
confluence. Cells were transfected using the Lipofectamine Plus reagent (Invitrogen, 
Groningen, Netherlands) in serum-free OptiMEM I medium (Invitrogen, Groningen, 
Netherlands) according to the manufacturer’s recommendations.  
Cells were incubated in OptiMEM I, including the transfection mix, for four hours at 
37°C. Subsequently, the serum free medium was replaced by supplemented RPMI 
medium. Puromycin selection [1µg/ml] was initiated on the following day and cells 
were harvested after 72h.  
 
2.2.4 Functional Assays  
2.2.4.1 Proliferation Assay 
ES cell lines were seeded (5x104 cells/ well) into 6-well plates, cultured in RPMI 1640 
or DMEM medium with 50ng/µl puromycin for constant selection pressure. 
Proliferation of viable cells was monitored by cell counting using a Bürker-Türk 
chamber in combination with trypan blue exclusion test for 4 days. Cells were treated 
with Accutase (PAA Laboratories, Linz, Austria), for 10 minutes and 10µl of the cell 
suspension were mixed with the same volume of trypan blue.  
2.2.4.2 Soft agar assay 
Cells were seeded in triplicates at 2 × 104 cells/35-mm dish. After resuspension in 
0.3% agar in 10% FCS and RPMI or DMEM, cells were plated in 0.6% agar-coated 
dishes. A top layer containing 0.6% agar was then added. Cells were fed every 5 
days by placing ~ 200µl of medium on the top layer. Colonies were microscopically 
counted after 14 days. Colony formation was examined at seven sites per well for a 
total of 21 fields. 
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2.2.5 Immunofluorescence analysis  
ES cells were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature 
(RT), washed with 1x PBS and permeabilized using 0.1-0.5% Triton X100/PBS for 10 
minutes. Cells were blocked with 2%-FCS/PBS for another 10 minutes and stained 
with anti-FLAG antibody (DYKDDDDK, Cell Signaling Technology, Inc., Danvers, 
MA) diluted in 2%FCS/PBS for 1 hour in a humid chamber at RT. After extensive 
washing with PBS, cells were incubated with secondary antibody (red-fluorescent 
Alexa Fluor 594 goat anti–rabbit IgG, Molecular Probes, Eugene, OR,) for 30 minutes 
in the dark, subsequently washed with PBS and counterstained with DAPI. 
2.2.6 Flow cytometric analysis 
For testing ES sensitivity to different concentrations of MSA for 16h, a no-wash 
sample preparation was conducted in which cells were gently harvested using 
Accutase (PAA Laboratories, Linz, Austria) and finally mixed with the corresponding 
supernatant (SN) to ensure a cell suspension containing all cell populations (dead, 
apoptotic, living). Each cell suspension was stained for Annexin V using FITC 
Annexin V antibody (BD Biosciences). The cell suspensions were incubated for 15 
min in the dark followed by addition of DAPI (0.03µg/ml; Sigma-Aldrich, St.Louis, 
MO) as a marker for cells referred to as non viable (166). After staining, cells were 
acquired on a BDTM LSRII flow cytometer.  
For cell-death rescue experiments using sh-FOXO1 and sh-scrambled control, cells 
were co-transfected using the low-expression eGFP-Plasmid (MSCV-MIGR1). 48h 
post transfection, cells were treated or not with 5µM MSA for 24h and subjected to 
flow cytometric cell viability analysis following a no-wash sample preparation as 
described above. Cells were stained for Annexin V using the APC Annexin V 
antibody (BD Biosciences) for 15 min in the dark including all further steps as 
described above. The gating strategy was as follows: First, cells were gated on SSC-
area versus FSC-width. Within this population the GFP-positive cells were identified 
using the FITC-A versus PerCP-A channel and the apoptotic and necrotic/dead cells 
were gated within the GFP-positive population on the APC-A versus DAPI-A channel. 
For data evaluation the FlowJo software (Version 7.6.3) was used. To validate the 
mRNA induction of FOXO1 by MSA as well as the knockdown of endogenous 
FOXO1, GFP pos. cells were sorted and RNA was extracted according to the 
manufacturer’s instructions (TRIzol Reagent, Invitrogen, Groningen, Netherlands). 
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2.2.7 In vivo studies 
An orthotopic xenotransplantation model, using the ES cell line SK-N-MC was used 
as described in (167). Briefly, 2 x 106 SK-N-MC Ewing sarcoma cells were directly 
injected into the M. gastrocnemius of 6-8 week-old female SCID/bg mice. Tumor 
formation was examined on a daily basis and MSA treatments begun when tumors 
reached measurable sizes. Two groups, consisting of 14 mice each, were either 
intraperitoneally injected with 2.5mg/kg MSA or PBS and treatments were conducted 
every second day for 2 weeks. Tumor dimensions were measured manually with a 
digital caliper obtaining 2 diameters of the tumor sphere to determine the total volume 
of the tumors. The lower extremity volume at the site of the tumor was determined by 
the formula (D x d2/6) x , where D is the longer diameter and d is the shorter 
diameter.  Experiments were terminated when tumors reached the critical volume of 
1500mm3. Mice studies were approved by the state regulatory board and all animals 
received human care in compliance with the respective guidelines. 
2.2.8 Bioinformatic analysis 
2.2.8.1 Microarray & in-silico motif analysis 
Gene expression profiling was performed using Affymetrix HG-U133-PLUS2 arrays 
(Affymetrix, Inc., Santa Clara, CA). cRNA target synthesis and GeneChip® 
processing were performed at the Gene Expression Profiling Unit of the Medical 
University of Innsbruck (Innsbruck, Austria) according to standard protocols 
(Affymetrix, Inc., Santa Clara, CA). Microarray data were performed in compliance to 
MIAME guidelines and submitted to GEO - Accession number GSE37409. All further 
analyses were performed in R statistical environment using Bioconductor packages 
(168). Affymetrix CEL files were preprocessed as described previously (129), yielding 
a final number of 8154 probesets that were used for all further analyses. Differentially 
expressed genes were determined using a moderated t-test in the R package “limma” 
(169). All P-values were corrected for multiple testing using the “Benjamini-Hochberg” 
correction method. 
Time-course analysis of gene expression in an ES cell line with a doxycycline 
inducible knockdown of EWS-FLI1 (A673sh) was performed on Affymetrix HGU-
133A2 arrays as follows: At five timepoints, 0h, 18h, 36h, 53h, 72h, RNA was 
extracted and subjected to microarray analysis where 0h marks the time when 
doxycycline was added. Each experiment was reiterated at least twice and the EWS-
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FLI1 protein was found to be consistently downregulated already at 18h in all 
replicate experiments. After filtering out probesets with very low expression values 
across all samples (R package “panp”), for every gene the most informative probeset 
(i.e. the one with the highest variance across all samples) was selected (R package 
“genefilter”) yielding 8023 genes for further analysis. Differential expression for each 
gene at each later timepoint against 0h was determined using a moderated t-test 
from the R package “limma”. The resulting p-values were corrected for multiple 
testing using the Benjamini-Hochberg method. 
2.2.8.2 Promoter analysis for binding sites of known transcription factors 
Coordinates of all conserved transcription factor binding sites (TFBS) were 
downloaded from the UCSC genome browser database (tfbsConsSites.txt) and hits 
for all sites within 1kb upstream of the TSS of all genes in the refGene.txt table were 
counted (both tables were downloaded from: 
http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/). Subsequently, the 
occurrence of each TFBS was correlated with gene expression change over time (all 
later time-points vs. h0 across all genes after the EWS-FLI1 knockdown. To count 
motifs in genes with similar time-course dynamics, genes were ordered by their 
logFC and binned into 100 equally sized bins (R-package “dr”). Within these bins 
motifs of all TFBS were counted and the counts plotted against the average logFC of 
the respective bin. Pearson correlation coefficients between number of motifs and 
mean logFC were recorded. 
2.2.8.3 Statistical analysis of in-vitro and in-vivo assay 
In-vitro data were analyzed by the unpaired t test with Welch's correction or with the 
one-sample t test using the Prism 5 for Windows (version 5.02) statistical software 
(GraphPad Prism Software, Inc.). Data shown in graphical format represent the 
means (±SEM), and a P value of <0.05 is considered statistically significant. 
To test for overall differences in the growth curves of MSA treated vs. untreated mice 
a distribution free permutation test was utilized as described (170). Additionally, a 
mixed linear model analysis was performed on log-transformed values. To test for 
differences between treated and untreated groups on each day separately, a 
Wilcoxon signed rank test was performed. The mixed linear model analysis and 
Wilcoxon tests were done in SPPS. For the permutation test the implementation at 
http://www.stat.ucl.ac.be/ISpersonnel/lecoutre/Tgca/english/index3.html was used. 
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3 Results 
3.1 EWS-FLI1 repressed genes show enrichment of recognition 
motifs for forkhead box (FOX) proteins.  
To elucidate the transcriptional network downstream of EWS-FLI1, we analyzed time-
resolved gene-expression profiles upon conditional EWS-FLI1 knockdown in A673sh 
cells. Promoter regions of knockdown responsive genes were analyzed for the 
presence of transcription factor binding motifs. Whereas EWS-FLI1 activated target 
gene promoters (suppressed upon modulation of EWS-FLI1) revealed strong 
enrichment of ETS binding motifs, EWS-FLI1 repressed gene promoters (activated 
upon EWS-FLI1 silencing) showed prominent over-representation of recognition 
motifs for forkhead box (FOX) transcription factors (i.e. FOXA2, FOXD1, FOXF2, 
FOXI1, FOXJ2, FOXL1, FOXO1, FOXO4) while lacking enrichment of ETS motifs 
(Figure 7). This result suggests a role for FOX family members in EWS-FLI1 
mediated gene repression. 
 
 
 
 
Figure 7: FOX motifs are enriched in EWS-FLI1 repressed genes.  
Result from the correlation analysis of gene expression with motif occurence. X-Axis: DNA Motifs from 
Transfac ; Y-Axis: Pearson correlation of gene expression change at time-point h36 (against h0) of 
conditional EWS-FLI1 suppression in A673sh cells with the number of motifs. Forkhead-box motifs are 
marked by red squares.  
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3.2 Several FOX proteins, including FOXO1 and FOXO3, are 
regulated by EWS-FLI1 at the transcriptional level. 
The enrichment of FOX motifs within EWS-FLI1 repressed promoters prompted us to 
investigate which FOX candidates are per se regulated by EWS-FLI1 in ES. 
Inspection of expression data of the inducible EWS-FLI1 knockdown as well as of 5 
additional ES cell lines with transient EWS-FLI1 knockdown (previously described 
(129)) revealed consistently differential expression of FOXO1 and of the related 
FOXO3 between control and EWS-FLI1 knockdown conditions (Figure 8A and (129)).  
 
 
 
Figure 8: Various FOX proteins are transcriptionally repressed by EWS-FLI1 
(A) Time resolved expression of FOX genes upon knockdown of EWS-FLI1 in A673sh cells. Only 
genes with probesets that passed quality filtering (see M&M section) are shown. (B) Sequence motifs 
of DNA motifs predicted to be specifically recognized by individual A673 expressed FOX-factors. 
 
Furthermore, FOXO1 is expressed at lower levels in primary ES as compared to a 
wide variety of tissues (153) (Figure 9A) and its promoter is directly bound by EWS-
FLI1 in ChIP-seq (our unpublished data) and ChIP-PCR experiments (Figure 
10;(171)). The FOXO3 promoter, on the other hand, was not directly bound by EWS-
FLI1 in ChIP-seq (data not shown) and shows higher expression in ES than in most 
other tissues (Figure 9B). Finally, position weight matrices (sequence logos, Figure 
8B) of ES expressed FOX-factors (Figure 8A) were found to be very similar. 
Therefore, combining motif analysis with gene expression data, FOXO1 and FOXO3 
were considered as the main candidate master regulatory transcription factors for a 
repressive transcriptional subsignature downstream of EWS-FLI1. 
A B 
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Figure 9: Dot plot of normalized gene expression values  
(A) FOXO1 (B) FOXO3. Data taken from (129). Blue: Reference tissues from (172). Red: primary 
Ewing Sarcoma samples. The comparison of A and B shows that FOXO1 is "off" in comparison to a 
wide variety of reference tissues, while FOXO3 is "on". 
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Figure 10: Representative ChIP-PCRs in A673sh cells. 
Two different FOXO1 promoter fragments (from -961 to -736 and  from -609 to -412 upstream of the 
transcription start site) including the ChIP-Seq hit at position -534 to -298, respectively and, for control, 
on a region further upstream (-9071 to -8888). Signals for EWS-FLI1 binding were obtained 
exclusively for the two promoter fragments in the presence of EWS-FLI1, but was completely 
abrogated upon 48h of doxycycline induced knockdown of EWS-FLI1. Input DNA and ChIPs using an 
IgG control antibody were used for specificity control. 
 
 
3.3 Subcellular localization of FOXO1 is regulated by EWS-FLI1.  
To test if reconstituted FOXO1 or FOXO3 can rescue expression of a subset of EWS-
FLI1 repressed genes (induced mRNA expression upon EWS-FLI1 knockdown and 
predicted to have FOXO1/3 binding sites using ConSite (http://asp.ii.uib.no:8090/cgi-
bin/CONSITE/consite)), we performed transient transfections to ectopically express 
these FOXO constructs as Flag-tagged proteins in A673sh cells. Following RNA 
extraction and subsequent cDNA synthesis, RT-PCR was performed and mRNA 
expression of 5 selected genes (EPAS1, HEY1, PLAT, DDIT4, LOX) was analysed 
(data not shown). No significant influence on the gene expression of these genes 
compared to EWS-FLI1 knockdown conditions was observed. However, since 
nuclear localization of FOXO proteins is a prerequisite for their transcriptional activity, 
we analysed whether the subcellular localization of ectopically expressed FOXO1 
and FOXO3 was affected by EWS-FLI1. 
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In fact, in the presence of EWS-FLI1, both ectopic FOXO1 and FOXO3 were found 
excluded from the nucleus. Upon silencing of EWS-FLI1, however, Flag-FOXO1 but 
not Flag-FOXO3 readily translocated to the nucleus (Figure 11A).  
 
 
Figure 11: The subcellular localization of FOXO1 in A673sh cells is dependent on EWS-FLI1.  
(A) Immunofluorescence analysis of FOXO1 and FOXO3 subcellular localization in the presence or 
absence of EWS-FLI1. Flag-tagged FOXO1 or FOXO3 was transfected into A673sh cells in the 
absence and presence of doxycycline induced EWS-FLI1 knockdown for 48 hours post transfection 
and subcellular localization was monitored by immunofluorescence using FLAG-tag specific antibody 
(red) with DAPI counterstain to delineate cell nuclei (blue). In the presence of EWS-FLI1, FOXO1 and 
FOXO3 stainings were confined exclusively to the cytoplasm. Upon EWS-FLI1 knockdown, only 
ectopically expressed FOXO1 but not FOXO3 translocated to the nucleus. (B) Immunoblot analysis of 
endogenous FOXO1 expression in cytoplasmic and nuclear cell fractions of A673sh cells. Basal 
expression of endogenous FOXO1 and FOXO3 in the presence of EWS-FLI1 was detectable 
exclusively in the cytoplasm. However, upon knockdown of EWS-FLI1 by doxycycline treatment for 
48h, FOXO1 expression was significantly increased and also expressed in the nucleus, whereas 
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FOXO3 remained in the cytoplasm. In concordance with this observation, the levels of inactive 
phosphorylated FOXO1 and FOXO3 were reduced upon knockdown of EWS-FLI1. Scale bars: 10µM   
 
We monitored endogenous FOXO1 and FOXO3 proteins upon doxycycline induced 
EWS-FLI1 knockdown by immunoblotting, and we observed strong FOXO1 induction 
and only weakly increased FOXO3 levels. FOXO1 was confined to the cytoplasm and 
the nucleus, whereas FOXO3 was exclusively retained in the cytoplasm (Figure 11B). 
While the cytoplasmic increase in FOXO1expression was already detectable at 16h 
of doxycycline treatment (the earliest time-point of EWS-FLI1 knockdown), nuclear 
FOXO1 was first observed at 36h (Figure. 12). 
 
Figure 12: Kinetics of endogenous FOXO1 protein expression upon doxycycline induced EWS-
FLI1 knockdown in A673sh cells.  
(A) Down-regulation of EWS-FLI1 was already observed at 16h, the time when cytoplasmic FOXO1 
induction became first detectable, while significant nuclear FOXO1 expression was first observed at 
36h of doxycycline treatment with strongest expression at 48h. (B) To assess the purity of 
cytoplasmic/nuclear protein fractions, the same samples used in (A) were probed for Tubulin and 
Lamin A/C expression vice versa. The blots from (A) and (B) were processed in parallel.      
 
Taken together, our findings suggest that EWS-FLI1 regulates FOXO1 not only at the 
transcriptional level but it also affects its subcellular localization thereby controlling 
the transcriptional activity of FOXO1. 
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3.4 CDK2 and AKT regulate FOXO1 activity in ES. 
 
The subcellular localization of FOXO1 and FOXO3 transcription factors is known to 
be mainly regulated by posttranslational phosphorylation (27, 173). Mining the gene 
expression data upon knockdown of EWS-FLI1 in A673sh cells and in 5 additional 
ES cell lines (129), and of our EWS-FLI1 ChIP-seq data, we identified cyclin-
dependent kinase 2 (CDK2), a well known negative regulator of FOXO1 
transcriptional activity (27, 38, 174), among EWS-FLI1 induced genes (Figure 13).  
 
Figure 13: CDK2 is a EWS-FLI1 induced target.  
(A) Kinetics of CDK2 mRNA expression in the EWS-FLI1 knockdown time-course of A673sh cells. X-
Axis: interval after doxycycline induced EWS-FLI1 knockdown. Y-Axis: log2 CDK2 mRNA expression. 
(B) CDK2 and FOXO1 protein expression in A673sh cells upon 48 hours EWS-FLI1 knockdown. (C) 
Luciferase reporter gene assay testing CDK2 promoter responsiveness to EWS-FLI1knockdown. Y-
axis: promoter activity of doxycycline treated relative to untreated cells (normalized for transfection 
efficiency and empty vector control transfections). Means and standard deviations of at least three 
independent experiments, each performed in triplicate, are shown. 
 
Additionally, it has been reported that PI3K/AKT mediated phosphorylation negatively 
regulates FOXO1/3 nuclear localization and consequently activity (175, 176). To 
investigate whether CDK2 and/or AKT play a role in nuclear exclusion of FOXO1/3 
downstream of EWS-FLI1, we treated A673sh cells with the inhibitors roscovitine and 
LY294002 alone, or in combination, to inhibit CDK2 and AKT activity, respectively 
(Figure 14A-B). Both inhibitors readily restored nuclear localization of ectopically 
expressed Flag-FOXO1 while Flag-FOXO3 remained in the cytoplasm. Coupled with 
the absence of nuclear translocation upon EWS-FLI1 knockdown, this result made 
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FOXO3 an unlikely candidate to participate in the gene regulatory network 
downstream of EWS-FLI1. 
 
 
Figure 14: Nuclear localization of FOXO1 but not FOXO3 is tightly regulated by AKT and CDK2.  
(A) Immunofluorescence analysis of A673sh cells transfected with either Flag-FOXO1wt or Flag-
FOXO3 and treated with 40µM of the PI3K/AKT inhibitor LY294002 or 40µM of the canonical CDK2 
inhibitor roscovitine, or a combination of both 48h post-transfection for 24h. Roscovitine and 
LY294002 treatments alone or in combination restore FOXO1 nuclear localization in the presence of 
EWS-FLI1, whereas FOXO3 remains in the cytoplasm. (B) Knockdown of endogenous CDK2 by 
shRNA-mediated RNA interference is sufficient to restore nuclear FOXO1 localization. A673sh cells 
were transfected with FLAG-FOXO1 and either shCDK2 or a scrambled shRNA control, and 
58 
immunofluorescence analysis was conducted 48h post-transfection. (C) Efficient CDK2 protein 
knockdown was monitored on the immunoblot. Results are representative of three experiments. Scale 
bars: 10µM   
 
To test the importance of CDK2- and AKT-mediated phosphorylation for the 
transcriptional activity of FOXO1, we transiently transfected A673sh cells with 
phosphorylation-resistant FOXO1 mutants. We used Flag-FOXO1- 
T24A/S256A/S319A (Flag-FOXO1-AAA) and Flag-FOXO1-S249A/S298A in which 
AKT, respectively CDK2 specific phosphorylation sites were converted to alanine (38, 
177). Both FOXO1 mutants localized to the nucleus but only Flag-FOXO1-AAA 
activated known FOXO1 target genes GADD45a, BTG1, and CDKN1A, despite the 
presence of EWS-FLI1 (Figure 15A-B).  
 
Figure 15: Nuclear localization and transcriptional activity of FOXO1 is rescued by mutation of 
inhibitory CDK2 and P-AKT phosphorylation sites.  
(A) A673sh cells were transfected with Flag-FOXO1wt, an AKT-resistant (T24A/S256A/S319A, (AAA)) 
or a CDK2-resistant version of Flag-FOXO1 (S249A,S298A), and immunofluorescence analysis was 
performed 48h post-transfection. Cells were stained by anti-Flag antibody and visualized by red-
fluorescent Alexa Fluor 594 goat anti–rabbit IgG antibody. (B) A673sh cells transfected with an AKT-
resistant version of Flag-FOXO1 were analysed by RT-PCR for mRNA expression of canonical 
FOXO1 targets such as GADD45a, BTG1 or CDKN1A and quantified using the image J software 
1.37v. Results are representative of three experiments performed. β-Actin was used as internal 
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control. GADD45a, growth arrest and DNA damage inducible alpha (entrez gene number: ID:1647); 
BTG1, B-cell translocation gene 1, anti-proliferative (ID:694); CDKN1A, cyclin-dependent kinase 
inhibitor 1A (ID:1026). Scale bars: 10µM 
 
Since treatment with roscovitine or mutation of residues S249 and S298 was 
sufficient to restore nuclear FOXO1 expression, we hypothesized that CDK2 played a 
central role in FOXO1 regulation downstream of EWS-FLI1. To test this, we 
performed knockdown experiments targeting endogenous CDK2 with specific shRNA 
in the presence of EWS-FLI1. As shown in Figure 14C, transiently transfected Flag-
FOXO1wt was only found in the nucleus when endogenous CDK2 was concomitantly 
silenced. No influence on subcellular FOXO1 localization was observed using a 
scrambled shRNA control. These results confirm a rate-limiting role for CDK2 in 
nuclear FOXO1 exclusion in EWS-FLI1 expressing ES cells. 
 
 
3.5 A repressive subsignature of EWS-FLI1 regulated genes is 
due to suppression of FOXO1.  
To test for the contribution of FOXO1 inactivation to the EWS-FLI1 repressive 
transcriptional signature, the overlap between genes activated upon EWS-FLI1 
knockdown and i) genes activated by ectopically expressed, nuclear directed 
FOXO1, and ii) genes re-activated after EWS-FLI1 knockdown with concomitant 
FOXO1 silencing were determined. In these experiments, 973 genes were found 
significantly (P<0.05, log2-foldchange>1) activated after EWS-FLI1 knockdown. Upon 
over-expression of AKT- or CDK2- phosphorylation resistant FOXO1 mutants, 208 
and 184 genes, respectively, were up-regulated by FOXO1 ( log2-foldchange>0.7). 
Of these, 94 and 58 genes respectively were also found up-regulated upon EWS-
FLI1 knockdown. These overlaps are highly significant (P < 10-10, hypergeometric 
test). A double-knockdown of FOXO1 and EWS-FLI1 resulted in down-regulation of 
306 genes (logFC<-0.7, P<0.05). The overlap of this gene set with 973 EWS-FLI1 
repressed genes contained 94 genes (P < 10-10, hypergeometric test). Thus, a 
significant overlap between FOXO1 activated and EWS-FLI1 repressed genes was 
identified as measured by three different approaches (Figure 16A). 
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Figure 16: A subset of EWS-FLI1 repressed genes is regulated by FOXO1.  
(A) Venn Diagramm showing the intersection between EWS-FLI1 repressed and FOXO1 activated 
genes. Over-expression of nuclear FOXO1 mutants (Flag-FOXO-T24A/S256A/S319A(AAA) (AKT-p-
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resistant), Flag-FOXO-S249A/S29A (CDK2-p-resistant) led to reactivation of 94 and 58 EWS-FLI1 
repressed genes, respectively, whereas silencing of reactivated endogenous FOXO1 under EWS-FLI1 
knockdown conditions prohibited activation of 94 EWS-FLI1 repressed genes.  (B) Validation of EWS-
FLI1 repressed genes that can be reactivated by nuclear FOXO1. A673sh cells were transfected with 
AKT- or CDK2-phosphorylation-resistant versions of Flag-FOXO1, and mRNA expression of 3 genes 
representative of the overlap between EWS-FLI1 repressed and FOXO1 activated genes was 
measured by RT-qPCR. (C) Representative Western Blot for protein expression of endogenous 
FOXO1 upon inducible EWS-FLI1 knockdown as well as ectopically expressed wild-type and nuclear 
FOXO1 mutant, corresponding to B, showing similar levels of ectopically expressed and induced 
endogenous FOXO1. (D) Representative FOXO1 protein expression corresponding to E, showing 
specificity and efficiency of sh-RNA mediated FOXO1 silencing (shRNA #3). β-Actin was used as 
loading control. (E) In addition, knockdown of reactivated endogenous FOXO1 was used to 
demonstrate the dependency of EWS-FLI1 mediated repression on FOXO1 silencing. The mRNA 
expression was normalized to pCDNA3 empty vector control expression or to sh-scrambled control 
without doxycycline treatment, and statistical relevance was analysed using the unpaired t-test or one-
sample t-test, respectively. B2M was used as internal control and doxycycline was applied for 72h. 
Results represent the mean ± SEM of two experiments performed. *p<0.05 and **p<0.01. 
 
Validation of these results was performed by RT-qPCR on three arbitrarily chosen 
genes from the overlap of genes that were found significant in all three experimental 
settings (Figure 16B-C). In contrast to wild-type FOXO1, introduction of AKT-
phosphorylation resistant FOXO1 significantly increased expression of EPAS1, MME 
and OSMR (Figure 16B and Figure 17E-F). In contrast, despite nuclear localization 
(Figure 15A), CDK2-phosphorylation resistant FOXO1 failed to reactivate these 
genes. This result may be explained by retention of intact AKT-mediated 
phosphorylation which is expected to lead to 14-3-3 binding and consequent FOXO1 
dissociation from DNA (178-180). Reactivation of endogenous FOXO1 as a 
consequence of doxycycline-induced EWS-FLI1 knockdown led to the transcriptional 
induction of all three tested genes, which was largely abolished upon RNAi 
knockdown of FOXO1 (Figure 16D-E). Similar results were obtained using a second 
shRNA targeting endogenous FOXO1 (Figure 17B-D). 
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Figure 17: mRNA expression of endogenous FOXO1 and of EWS-FLI1 upon modulation of 
EWS-FLI1 and FOXO1 in A673sh cells (related to Figure 16 B and E). 
(A-B) Doxycycline induced knockdown of EWS-FLI1 with concomitant FOXO1 silencing using two 
different FOXO1-shRNAs (#1, #3). (C) Representative FOXO1 protein expression showing specificity 
and efficiency of sh-RNA #1 mediated FOXO1 silencing and (D) comparable mRNA expression of the 
same genes (shown in Fig. 16E) upon knockdown of FOXO1 using shRNA #1. (E-F) FOXO1 and 
EWS-FLI1 mRNA expression upon ectopic expression of wild-type and mutant nuclear FOXO1. The 
mRNA expression was normalized to pCDNA3 empty vector control expression or to sh-scrambled 
control without doxycycline treatment. Statistical relevance was analysed using the unpaired t-test, 
B2M was used as internal control and doxycycline was applied for 72h. Results represent the mean ± 
SEM of two experiments performed. *p<0.05, **p<0.01 and ***p<0.001. 
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This result demonstrates the dependency of reactivation of these EWS-FLI1 
repressed genes on FOXO1 expression. Taken together, these data confirm our 
hypothesis that a repressive subsignature of EWS-FLI1 regulated genes is due to 
suppression of FOXO1. 
 
3.6 Functional restoration of nuclear FOXO1 expression in ES 
results in impaired proliferation and reduced colony formation 
capability.  
 
Since FOXO proteins are known to function as cell cycle regulators and, more 
specifically, can induce G1 arrest (22, 24), we asked whether restoration of nuclear 
FOXO1 functionally affects the proliferative activity of ES cells in vitro. A673sh and 
SK-N-MC cells were transfected with CDK2- and AKT-phosphorylation-resistant 
FOXO1 in the presence of EWS-FLI1. Control cells were transfected with empty 
vector or FOXO1wt. Proliferation of viable cells was monitored 4 days post 
transfection. As shown in Figure 18A-B, both A673sh and SK-N-MC exhibited 
significantly reduced proliferation upon restoration of nuclear FOXO1 compared to 
cells transfected with the empty vector control or FOXO1wt.  
The ability of cells to grow under anchorage-independent conditions is considered a 
hallmark of oncogenic transformation (181). When seeded into soft agar, the number 
of colonies formed by A673sh and SK-N-MC cells after 2 weeks was also significantly 
reduced upon expression of nuclear FOXO1 compared to cytoplasmic FOXO1wt and 
to the empty-vector control (Figure 18C-D). Since colony sizes did not differ 
dramatically between control-transfectants (empty-vector, FOXO1wt) and cells 
expressing nuclear-targeted FOXO1, the observed significant reduction in colony 
number cannot be solely attributed to reduced proliferation but to decreased 
clonogenicity. Taken together, these results suggest that FOXO1 plays an important 
role in ES oncogenesis. 
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Figure 18: Functional restoration of nuclear FOXO1 expression in ES cells results in impaired 
proliferation and reduced soft agar colony formation capability.  
A673sh (A, C) and SK-N-MC cells (B, D) were transfected with AKT- and CDK2- resistant FOXO1, or 
the empty vector control, or FOXO1wt. Experiments were performed in triplicates and one 
representative experiment of at least three is shown. (A) and (B) Anchorage-dependent growth. 
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Controls for FOXO1 protein expression are shown below the growth curves. (C) and (D) Clonogenicity 
of A673sh and SK-N-MC cells as studied by soft agar colony formation assays in vitro. The colony 
sizes (see corresponding pictures) were not found to be drastically different between controls (empty 
vector and FOXO1wt) and nuclear FOXO1 mutants, suggesting significantly reduced clonogenicity 
triggered by nuclear FOXO1. Colonies were counted 14 days after seeding. **p<0.01 and ***p<0.001. 
 
3.7 Methylseleninic acid (MSA) can reactivate endogenous 
FOXO1 in a dose- and time-dependent manner.  
Since we found endogenous FOXO1 to be negatively regulated by EWS-FLI1 at 
transcriptional and posttranslational levels in ES, a chemical compound, 
Methylseleninic acid (MSA), previously shown to reactivate FOXO1 in prostate 
cancer cells (150), was investigated for its potential to rescue FOXO1 activity in ES 
cells.  
 
 
Figure 19: MSA reactivates FOXO1 expression. 
MSA dose- (A) and time-dependent (B) FOXO1 protein induction as monitored by immuno blotting in 
different ES cell lines as indicated. Protein expression in (B) was quantified using the LICOR 
Odyssey® Infrared Imaging System. 
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Four different ES cell lines were treated with increasing MSA concentrations and the 
levels of endogenous FOXO1 protein were monitored by immunoblot analysis. As 
shown in Figure 19A, FOXO1 was induced in a concentration dependent manner with 
highest expression between 2.5 and 5µM MSA. FOXO1 protein expression peaked at 
16h (Figure 19B) while mRNA levels were already induced between 2h and 4h of 
MSA treatment and declined gradually thereafter (Figure 20A-B).  
 
Figure 20: FOXO1 mRNA expression is induced early upon treatment with MSA.  
Change of FOXO1 mRNA levels in (A) SK-N-MC and (B) A673 cells as a function of time measured by 
RT-qPCR. Shown are representative experiments of at least three, and the fold-induction was 
calculated in comparison to the untreated control and normalized to B2M. 
 
These findings suggest that MSA not only induces FOXO1 protein expression but 
also regulates FOXO1 at the RNA level. As shown in Fig. 19B, quantification of 
FOXO1 protein expression revealed 3 to 5 fold induction upon MSA treatment which 
was comparable to FOXO1 protein levels after the EWS-FLI1 knockdown (3 to 6 fold, 
data not shown).  
Notably, MSA treatments led to nuclear FOXO1 expression compared to the 
untreated control even in the presence of EWS-FLI1 in vitro and in vivo as shown for 
two different MSA treated tumours (MSA/1 and MSA/2) (Figure 21A-C). 
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Figure 21: MSA induces expression of nuclear FOXO1 in the presence of EWS-FLI1 in vitro and 
in vivo.  
The ES cell lines (A) SK-N-MC and (B) A673 were treated with 5µM MSA for 16h and subsequently 
processed to extract cytoplasmic and nuclear protein fractions. (C) Mice bearing orthotopic A673 
tumors where treated with 2.5mg/kg MSA every second day for three times and further processed to 
generate cytoplasmic and nuclear protein fractions from fresh tumor tissues. Nuclear FOXO1 
expression was elevated in MSA treated tumors (MSA/1 and MSA/2) compared to a PBS control. 
Protein expression was quantified using the LICOR Odyssey® Infrared Imaging System that allows 
linear quantification. Nuclear and cytoplasmic fractions were obtained using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagent kit as described in materials and methods section 2.1.8. The protein 
samples were probed with FOXO1 specific, p-FOXO1 (AKT-S256) and P-AKT (Thr 308) antibodies. 
LaminA/C and α-Tubulin were used as nuclear and cytoplasmic loading controls, respectively. 
 
This observation was accompanied by reduced cytoplasmic p-FOXO1 levels, 
presumably as a consequence of MSA induced reduction of P-AKT (151, 182) 
(Figure 21A-B). 
3.8 MSA induces cell death which is dependent on FOXO1 
expression.  
To analyse the effect of MSA on ES cell survival, A673 and SK-N-MC cell lines were 
treated with different concentrations of MSA for 16h and subsequently processed for 
flow cytometric cell death analysis. The percentage of AnnexinV-FITC positive cells, 
representing the apoptotic sub-population, and DAPI positive necrotic cells were 
counted together to monitor overall cell death induction as shown in Figure 22A. At a 
final concentration of 5µM MSA, the proportion of drug-induced cell death 
approached 30-40% in both cell lines.  
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To clarify whether FOXO1 was involved in MSA induced cell death, we transiently 
transfected SK-N-MC and A673 ES cell lines with either sh-scrambled control or sh-
RNA targeting endogenous FOXO1 (sh-FOXO1 #3) following MSA treatment (5µM) 
for 24h (Figure 22B and for control 22C-D). In both cell lines, induction of cell death 
as a function of AnnexinV-APC and DAPI positive cells was induced in sh-scrambled 
controls, whereas the knockdown of endogenously induced FOXO1 significantly 
reduced the MSA effect, suggesting that FOXO1 is at least partially involved in MSA 
induced cell death. 
 
 
Figure 22: MSA induces ES cell death in vitro. 
(A) MSA induces dose dependent cell death in vitro as measured by flow cytometry after 16h of 
treatment. (B) MSA induced cell death of A673 and SK-N-MC cells can be partially rescued by 
A 
B 
C D 
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transient knockdown of endogenous FOXO1. FOXO1 mRNA was readily reduced when ES cell lines 
(C) SK-N-MC and (D) A673 were transfected with sh-RNA targeting endogenous FOXO1 compared to 
the sh-scrambled control, as assessed by RT-qPCR. Results are representative of four experiments 
and the fold induction was calculated based on the untreated control, and B2M was used as internal 
control. Statistical analysis was done using the unpaired t test. 
 
3.9 MSA reduces ES growth in vivo.  
 
To assess the potential of MSA to reduce ES tumor growth in-vivo, we used an 
orthotopic mouse xenotransplantation model. 2 x 106 SK-N-MC cells were directly 
injected into the M. gastrocnemius of SCID/bg mice. Tumor formation was examined 
on a daily basis and treatments begun when tumors reached measurable sizes. A 
total of 14 mice per group (MSA or PBS) were treated with 2.5mg/kg MSA or the 
equivalent volume of PBS every second day for a time period of 2 weeks.  
 
 
 
 
Figure 23: MSA reduces ES tumor growth in vivo. 
MSA reduces ES tumor growth in vivo. After orthotopic injection of 2 x 106 SK-N-MC cells in the m. 
gastrocnemius, mice were either treated with 2.5mg/kg MSA (n=9) or PBS (n=12) every second day 
for 14 days. Tumor growth was further monitored until day 21. A distribution-free test for tumor-growth 
curve analyses revealed an overall significant difference between the MSA group versus the PBS 
group (P= 0.0403). Furthermore, significant differences were observed between the MSA group and 
the PBS group at different times as measured by Wilcoxon two sample test (day 10, P=0.04283; day 
12, P=0.03604; day 14, P= 0.04283; day 19, P=0.02518; day 21, P=0.01565) *p<0.05. 
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Mice bearing tumors bigger than 100 mm3 at day 0 were excluded from the analysis 
to avoid heterogeneity in MSA take-rate (183). Mice were observed for a period of 21 
days after starting MSA treatments. As shown in Figure 23, tumor growth was 
significantly reduced in the MSA group compared to PBS control mice. Notably, the 
MSA mediated inhibitory growth effect on ES tumors persisted beyond the treatment 
period and tumor growth delay was accompanied by increased FOXO1 protein levels 
(Figure 24), suggesting a potent anti-tumorigenic activity of MSA. 
 
 
 
 
Figure 24: MSA induces FOXO1 expression and reduces ES tumor growth in vivo.  
(A) Representative H&E stains of tumors from mice treated with PBS (mouse 4.3) or with 2.5mg/kg 
MSA (mouse 6.5) every second day for 2 weeks. Scale bar: 100 μm (first row); 20 μm (second row). 
(B) Immunoblot analysis on the tumors from A showed that MSA treatments induced FOXO1 
expression compared to the PBS control. (C) Tumor volume over time from mice shown in A and B. 
Whereas PBS treatments led to exponential tumor growth, MSA treatments prohibited ES tumor 
growth consistent with induced FOXO1 expression. 
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4 Discussion 
Because of its specificity to ES and its proven involvement in ES oncogenesis and 
progression (141, 184, 185), EWS-FLI1 is considered to be the ideal therapeutic 
target for future ES treatment strategies (124). Unfortunately, it has been difficult to 
therapeutically target nuclear transcription factors. Consequently, intervention with 
the downstream transcriptional network of EWS-FLI1 may be an alternative option to 
treat ES. However, the mechanisms of transcriptional regulation by EWS-FLI1 are 
only partially understood. So far, very little is known about mechanisms of EWS-FLI1 
mediated gene repression, even though there is evidence that part of its repressive 
signature can be assigned to the activation of transcriptional repressors such as 
NKX2.2 or NR0B1 (156, 157). Moreover, it has been recently shown that EWS-FLI1 
can mediate gene repression via transcriptional and posttranscriptional mechanisms 
(158). 
Here we report that EWS-FLI1 exerts a significant part of its transcriptional 
repression activity via inhibition of the forkhead transcription factor FOXO1. Our in 
vitro data show that FOXO1 is tightly regulated in a multilayered manner by EWS-
FLI1 mediated transcriptional repression and inhibitory phosphorylation by EWS-FLI1 
induced CDK2 and AKT (summarized in Figure 25).  
 
Figure 25: The transcriptional activity of FOXO1 is regulated in a multilayered manner.  
EWS-FLI1 not only represses the transcription of FOXO1 but also affects P-AKT levels and regulates 
CDK2 activity, thus regulating FOXO1 transcriptional activity on a post-translational level. Blocking the 
PI3K-AKT signaling pathway with the canonical PI3K inhibitor LY294002 or by blocking active CDK2 
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with roscovitine can overcome the repressive effect of EWS-FLI1 as shown for ectopically expressed 
FOXO1wt. 
 
There is ample experimental evidence that AKT and CDK2 regulate the subcellular 
localization of FOXO1 independently of each other. In ES, the PI3K pathway is 
known to be an essential pro-survival  pathway (186) which can be activated by 
growth factors such as IGF-1. It was previously shown that insulin-like growth factor 
binding protein-3 (IGFBP-3) is directly suppressed by EWS-FLI1 which at least 
partially enables ES cells to strongly activate this signaling pathway (130). Treatment 
with recombinant IGFBP-3 drastically decreases levels of phosphorylated AKT in ES 
cells (130) as a consequence of reduced IGF-1 levels and subsequently decreased 
phosphorylation of IGF-1R and p-AKT (163). Consistent with these findings, our 
immunofluorescence analysis revealed that by using a phosphorylation-resistant 
version of FOXO1, AKT mediated nuclear exclusion was abrogated. On the other 
hand, CDK2 was reported to functionally interact with FOXO1 leading to 
phosphorylation at two specific serine residues (S249/S298) followed by nuclear 
exclusion (38). Interestingly, ChIP-seq analysis and reporter gene assays identified 
CDK2 as a EWS-FLI1 induced target, suggesting an important role for CDK2 in 
FOXO1 repression by EWS-FLI1. Here, we show that knockdown of CDK2 was 
sufficient to drive ectopically expressed FOXO1 into the nucleus of ES cells even in 
the presence of active PI3K/AKT signaling. This finding is supported by nuclear 
localization of a CDK2-resistant FOXO1 mutant (S249A/S298A). While AKT 
phosphorylation at residues T24 and S256 causes binding of chaperon protein 14-3-
3 (176, 187), potentially masking the nuclear localization signal (NLS) and causing 
dissociation of FOXO1 from DNA (178, 187), CDK2 phosphorylation at S249 does 
not affect 14-3-3 binding (38) but increases the negative charge of an adjacent 
stretch of three arginines within the NLS (38), which was previously demonstrated to 
play a major role in FOXO3 nuclear localization (49). However, the CDK2-
phosphorylation-resistant version (S249A/S298A) of FOXO1 is still exposed to AKT-
mediated phosphorylation thus allowing for 14-3-3 mediated destabilization of 
FOXO1 on DNA. Therefore, it was not unexpected that over-expression of CDK2-
mutant FOXO1 did not re-activate EWS-FLI1 repressed genes to the same extent as 
AKT phosphorylation resistant FOXO1. The latter was capable of reactivating about 
10% of EWS-FLI1 repressed genes as opposed to only 6% reactivated by CDK2-
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resistant FOXO1. FOXO1 suppression by RNAi prohibited the activation of a similar 
number of genes by EWS-FLI1 knockdown as by the AKT resistant mutant.  
FOXO1 was demonstrated to be involved in cellular differentiation (reviewed in (35)), 
and more specifically to function as an early molecular regulator in the differentiation 
of mesenchymal cells into osteoblasts (188). Along these lines, Tirode et al. reported 
previously that long-term inhibition of EWS-FLI1 enables differentiation of ES cells 
into the osteogenic lineage when treated with a suitable differentiation cocktail (98). 
Thus, reactivation of FOXO1 may represent an appropriate tool to induce 
differentiation in ES. Consistent with FOXO1-induced regulation of proliferation via 
induction of cell cycle arrest (189-191), our in vitro assays revealed reduced 
proliferative ability of ES cells upon restoration of nuclear FOXO1. In addition, 
nuclear FOXO1 decreased the clonogenicity of ES cells in soft agar, suggesting that 
FOXO1 plays an important role in ES oncogenesis.  
Since our results identify the tumor suppressor FOXO1 as a potent negative regulator 
of cell proliferation and anchorage-independent growth in vitro, we hypothesized that 
reactivation of endogenous FOXO1 in the presence of EWS-FLI1 may constitute a 
potentially promising therapeutic strategy for ES. As a proof of principle, we chose to 
interrogate a small molecule, MSA, previously demonstrated to reactivate FOXO1 in 
prostate cancer cells, for its activity in ES cells in vitro and in vivo.  
Selenium, as an essential component of the human diet, has long been discussed as 
a potential agent for cancer prevention (192-195). In a randomized, double-blinded, 
placebo-controlled human study (Nutritional Prevention of Cancer Trial (NPC)), more 
than 1300 patients were treated with a daily dose of 200µg selenized yeast as source 
for nutritional selenium supplementation in order to reduce the risk of recurrent non-
melanoma skin cancer (192). Interestingly, the NPC study revealed a significant 
protective effect of selenium supplementation on the overall incidence of prostate 
cancer, especially in patients with a low baseline of plasma selenium concentrations 
(193, 194). This effect was largely attributed to selenite in the yeast, which is rapidly 
excreted via feces and urine. Based on the findings of NPC, the Selenium and 
Vitamin E Cancer Prevention Trial (SELECT) was initiated but prematurely 
terminated in 2008 because it failed to reduce prostate cancer incidence (196). 
These contradictory findings of the NPC and SELECT studies have been discussed 
as possibly arising from the use of different selenium formulations. 
Selenomethionine, used in SELECT, was suggested to be ineffective due to its rapid 
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incorporation into proteins which limits its bio availability in the plasma where it has 
been proposed to exert its anti-cancer activity (197). In contrast, mono-methylated 
forms of selenium, methylseleninic acid (MSA) and methylselenocysteine (MSC), 
which are rapidly metabolized to methylselenol, have been proposed to be active 
against a variety of cancers (198). MSA was shown to be more effective than MSC or 
Selenite in a prostate cancer xenograft model (199, 200). Moreover, it was 
demonstrated to act synergistically with several established chemotherapeutic agents 
including Doxorubicin and Etoposide, two components of standard chemotherapy in 
ES patients (201).   
We found that ES cell-lines were highly sensitive to MSA treatment. MSA was 
previously shown to be involved in induction of apoptosis by different mechanisms 
(202, 203). We here demonstrate that cell death induction in ES was at least partially 
dependent on MSA-induced FOXO1 activity. We also observed anti-tumor activity in 
an orthotopic ES xenograft model which was accompanied by elevated FOXO1 
protein levels consistent with our hypothesis that FOXO1 activation downstream of 
EWS-FLI1 confers a therapeutic benefit. However, the mechanism of FOXO1 
reactivation by MSA remains elusive. MSA was demonstrated to reduce IGF1R levels 
and, consequently, phospho-AKT levels in a mouse mammary hyperplastic epithelial 
cell-line (204) providing a possible explanation for the post-translational FOXO1-
inducing activity of the drug. A study in prostate cancer cells revealed that MSA 
treatment results in decreased expression of genes involved in metabolism, 
angiogenesis, certain transcription factors and, interestingly, signal transduction 
(ERK and AKT), which was significantly higher in tumor cells than in non-tumor cells 
(205). 
High selenium doses are often associated with intoxication, and the MSA 
concentration used in this study (2.5mg/kg) represents the highest tolerated dose in 
SCID/bg mice (data not shown). For potential clinical use, we envision combination of 
low-dose methylated selenium in combination with other standard chemotherapeutic 
agents, since it was reported that MSA synergizes with conventional drugs such as 
etoposide and doxorubicin, which are frequently used in the treatment of Ewing 
sarcoma (205). 
Taken together, our results imply that FOXO1 acts as a tumor suppressor in ES, and 
identify FOXO1 reactivation as a promising strategy for a future ES specific therapy.  
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